"Rush"

To. Jan

Access DB# 91089

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Brian Kwon Examiner #: 78155 Date: 4/8/03
Art Unit: 1614 Phone Number 308-5399 Serial Number: 09/835099
Mail Box and Bldg/Room Location: CM1 2D04 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: neurodegenerative disease

Inventors (please provide full names): Bamdad et al

Earliest Priority Filing Date: 4/12/2002

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

☆ method of treatment: neurodegenerative disease caused by fibril or aggregate
e.g. Alzheimer, Type II diabetes, DIC (Disseminated Intravascular coagulation), Parkinsons, Huntington, Amyloidosis,

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

****

STAFF USE ONLY

Searcher: Jan
Searcher Phone #: 4498
Searcher Location:
Date Searcher Picked Up: 4/9/03
Date Completed: 4/9/03
Searcher Prep & Review Time:
Clerical Prep Time: 30
Online Time: 1 hr 20

Type of Search		Vendors and cost where applicable	
NA Sequence (#)		STN	✓
AA Sequence (#)		Dialog	
Structure (#)	✓	Questel/Orbit	
Bibliographic	✓	Dr.Link	
Litigation		Lexis/Nexis	
Fulltext		Sequence Systems	
Patent Family		WWW/Internet	
Other		Other (specify)	

PTO-1590 (8-01)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

=> d all hitstr tot

L127 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:978470 HCAPLUS
DN 138:33365
TI Compositions and methods for the treatment of **Parkinson**'s disease with quinoline ring-containing **neuromelanin**-binding compounds
IN Nelson, Jodi
PA USA
SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,417,177.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K031-4706
NCL 514313000
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2002198231	A1	20021226		US 2002-192414	20020709	<--
	US 6417177	B1	20020709		US 2000-615639	20000713	<--
PRAI	US 1999-143767P	P	19990713	<--			
	US 2000-175051P	P	20000107	<--			
	US 2000-202140P	P	20000505	<--			
	US 2000-615639	A2	20000713	<--			

AB This invention provides compns. and methods for increasing cellular respiration of melanized catecholamine **neurons**, and methods for alleviating symptoms or stopping appearance and/or progression of symptoms of **Parkinson**'s disease and related conditions, characterized by nigrostriatal degeneration. An effective amt. of a **neuromelanin** -binding compn. having a quinoline ring in a suitable pharmaceutical carrier is administered to patient in need of such treatment. Preferably the compn. comprises (-)-chloroquine. Selected adjuvants are also provided as part of the compns. of this invention.

ST **Parkinson** disease treatment chloroquine compd; **antiparkinsonian** quinoline ring contg **neuromelanin** binding compd; melanized catecholamine **neuron** respiration chloroquine compd

IT Antihistamines
(H1, enhancing agent adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT **Brain**
(adjuvant targeting; quinoline ring-contg. **neuromelanin** -binding compds. for treatment of **Parkinson**'s disease)

IT Antioxidants
Dopamine agonists
Radical scavengers
(adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Lactoferrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibody to, conjugates with chloroquine compd.; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT **Nerve**
(catecholaminergic, increasing cellular respiration of melanized; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Lipophilicity
(chloroquine compd. conjugates with agent having; quinoline ring-contg.

neuromelanin-binding compds. for treatment of **Parkinson**'s disease)

IT Antibodies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, with chloroquine compd., to lactotransferrin; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Respiration, animal
(enhancement of melanized catecholamine **neurons**; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Drug delivery systems
(immunoconjugates, anti-lactotransferrin antibody conjugates with chloroquine compd.; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT **Nervous system**
(multiple system atrophy; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Melanins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**neuromelanins**, quinoline ring-contg. compd. binding to; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Cytoprotective agents
(**neuroprotectants**, adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT **Brain, disease**
(nigrostriatal **degeneration**; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Metabolism, animal
(peripheral, inhibitor of; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Cell membrane
(protective agent as adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT **Antiparkinsonian agents**
Cognition enhancers
Drug delivery systems
Enantiomers
Human
Parkinson's disease
(quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Salts, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Mixtures
(racemic; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Eye
(retina, protective agent as adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT Drug delivery systems
(timed-release; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT **51-61-6**, Dopamine, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT 50-81-7, Vitamin C, biological studies 73-31-4, Melatonin 128-37-0, Butylated hydroxytoluene, biological studies 1406-18-4, Vitamin E 9054-89-1, Superoxide dismutase 23288-49-5, Probucol 25013-16-5, Butylated hydroxyanisole 174882-69-0, Pycnogenol
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antioxidant adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT 299-28-5, Calcium gluconate 814-80-2, Calcium lactate 1406-16-2, Vitamin D 7693-13-2, Calcium citrate 10103-46-5, Calcium phosphate 14127-61-8, Calcium ion, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as peripheral membrane protective agent; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT 1951-25-3, Amiodarone **51481-61-9**, Cimetidine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cytochrome P 450 2D6 and A3 inhibitor inhibiting peripheral metab. of chloroquine compds.; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT 56-54-2, Quinidine 60-99-1, Levomepromazine 132-22-9, Chlorpheniramine 303-49-1, Clomipramine 364-62-5, Metoclopramide 54910-89-3, Fluoxetine 61869-08-7, Paroxetine 66357-35-5, Ranitidine 71320-77-9, Moclobemide 79617-96-2, Sertraline 91161-71-6, Terbinafine 116644-53-2, Mibefradil 155213-67-5, Ritonavir 169590-42-5, Celecoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytochrome P 450 2D6 inhibitor inhibiting peripheral metab. of chloroquine compds.; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT 114-07-8, Erythromycin 147-84-2, biological studies 42399-41-7, Diltiazem 54739-18-3, Fluvoxamine 65277-42-1, Ketoconazole 70458-96-7, Norfloxacin 81103-11-9, Clarithromycin 83366-66-9, Nefazodone 83891-03-6, Norfluoxetine 84371-65-3, Mifepristone 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 127779-20-8, Saquinavir 136817-59-9, Delavirdine 150378-17-9, Indinavir 159989-64-7, Nelfinavir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytochrome P 450 A3 inhibitor inhibiting peripheral metab. of chloroquine compds.; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT 58-33-3, Promethazine hydrochloride 58-73-1, Diphenhydramine 59-33-6, Pyrilamine maleate 91-81-6, Tripelenamine 113-92-8, Chlorpheniramine maleate 303-25-3, Cyclizine hydrochloride 523-87-5, Dimenhydrinate 980-71-2, Brompheniramine maleate 1104-22-9, Meclizine hydrochloride 2192-20-3, Hydroxyzine hydrochloride 3505-38-2, Carbinoxamine maleate 5897-19-8, Cyclizine lactate 10246-75-0, Hydroxyzine pamoate 15686-51-8, Clemastine 50679-08-8, Terfenadine 68844-77-9, Astemizole 79794-75-5, Loratadine 83881-52-1, Cetirizine hydrochloride 87848-99-5, Acrivastine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**histamine** H1 receptor antagonist as enhancing agent adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT 329322-82-9, Cytochrome P450 3A 330597-62-1, Cytochrome P450 2D6
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitor of; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT 50-63-5, Chloroquine phosphate 54-05-7, Chloroquine 118-42-3, Hydroxychloroquine 134-31-6, 8-Quinolinol sulfate 442-96-6 1915-92-0 2739-16-4 4169-19-1, 1-Acetyl-1,2,3,4-tetrahydroquinoline 4298-15-1 6168-85-0 24283-71-4, 1-Butyryl-1,2,3,4-tetrahydroquinoline 32571-37-2 53462-15-0 58175-87-4, (-)-Chloroquine 82351-01-7 99218-67-4 319912-96-4 319912-97-5 319912-98-6 319912-99-7 319913-00-3 319913-01-4 319913-03-6 319913-04-7 319913-05-8 319913-06-9 319913-07-0 319913-08-1 478784-57-5 478784-58-6 478784-60-0 478784-61-1 478784-63-3 478784-64-4 478784-65-5 478784-66-6 478784-67-7 478784-68-8 478784-70-2 478784-71-3 478784-73-5 478784-74-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

IT **51-61-6**, Dopamine, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvant; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

RN 51-61-6 HCAPLUS
CN 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) (CA INDEX NAME)



IT **51481-61-9**, Cimetidine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cytochrome P 450 2D6 and A3 inhibitor inhibiting peripheral metab. of chloroquine compds.; quinoline ring-contg. **neuromelanin**-binding compds. for treatment of **Parkinson**'s disease)

RN 51481-61-9 HCAPLUS
CN Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L127 ANSWER 2 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:793363 HCAPLUS
DN 137:304808
TI Methods and compounds for decreasing **cell toxicity** or death
IN Yuan, Junying; Sanchez, Ivelisse
PA President and Fellows of Harvard College, USA
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2

DT **Patent**
LA English
IC ICM A61K
CC 1-12 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080855	A2	20021017	WO 2002-US11025	20020409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002155172	A1	20021024	US 2001-829040	20010409 <--
PRAI	US 2001-829040	A	20010409		
	US 2000-195661P	P	20000407 <--		

AB The invention features methods for decreasing cell toxicity or death, and for decreasing polyglutamine **aggregates** and other **amyloidogenic aggregates**. The invention also features methods for treating a subject with a condition in which expanded polyglutamine repeats or **amyloidogenic aggregates** are present.

ST cell death inhibitor polyglutamine **aggregate** decrease; **amyloidogenic aggregate** decrease cell death inhibitor; Congo Red analog cell death polyglutamine **aggregate**

IT **Nervous system**
(**Huntington's chorea**; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**amyloidogenic**; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT Human
Mammalia
Rodentia
(cell; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT **Nervous system**
(degeneration; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT **Brain, disease**
(dentatorubral-pallidoluysian atrophy; methods and compds. for decreasing cell toxicity or **death** by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT **Schizophrenia**
(familial; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT Fertility

(male, disorder; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT Cell death
Clover (Trifolium pratense)
Cytoprotective agents
Cytotoxicity
Drug delivery systems
Drug screening
Gamete and Germ cell
High throughput screening
Translation, genetic
(methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT Spinal muscular atrophy
(spinal and bulbar muscular atrophy; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT **Nervous system**
(spinocerebellar ataxia; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT 2829-42-7, Direct Yellow 26
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Direct Yellow 26; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT 179241-78-2, Caspase 8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT 573-58-0, Congo Red
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT 50-23-7, Hydrocortisone 52-86-8, Haloperidol 59-99-4D, Neostigmine, derivs. 68-41-7, D-Cycloserine 92-87-5D, [1,1'-Biphenyl]-4,4'-diamine, derivs. 94-78-0, Phenazopyridine **125-33-7**, Primidone 446-86-6, Azathioprine 613-35-4 1309-48-4, Magnesium oxide, biological studies 2429-84-7, Direct Red 1 2444-46-4, N-Vanillylnonamide 2623-51-0 2921-57-5 6459-87-6 6637-88-3, Direct Orange 6 6655-95-4, Direct Blue 158 8005-72-9, Direct Yellow 28 14611-52-0, (-)-Deprenyl hydrochloride 20830-75-5, Digoxin 22260-51-1, Bromocriptine mesylate 34977-63-4, Direct Black 51 42924-53-8, Nabumetone 54579-28-1, C.I. Direct Orange 1 64083-59-6, Direct Orange 8 75535-02-3 78374-79-5 82859-73-2 109019-05-8 109504-77-0 299199-67-0 303215-90-9 305858-09-7 312749-40-9 330220-26-3 331856-01-0 349653-80-1 351987-68-3 364600-08-8 385790-72-7 404852-48-8 413617-33-1 414887-35-7 470688-32-5 470688-33-6 470688-34-7 470688-35-8D, derivs. 470688-36-9D, derivs. 470688-37-0 470697-02-0 470697-03-1 470697-04-2

RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT 26700-71-0, Polyglutamine 69864-43-3, Polyglutamine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(repeats; methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

IT **125-33-7**, Primidone
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(methods and compds. for decreasing cell toxicity or death by decreasing polyglutamine or **amyloidogenic** proteins **aggregates** using Congo Red and related compds. in relation to mechanism)

RN 125-33-7 HCAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



L127 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:522639 HCAPLUS
DN 137:73276
TI Behavior chemotherapy for prevention of **Alzheimer**'s disease
IN Eig, Mark H.
PA USA
SO U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. 6,333,357.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K031-55
ICS A61K031-44; A61K031-343; A61K031-137
NCL 514355000
CC 1-11 (Pharmacology)
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2002091145	A1	20020711		US 2001-992972	20011113	<--
	US 6333357	B1	20011225		US 1999-434286	19991105	<--
	AU 2001018105	A5	20020611		AU 2001-18105	20001201	<--
PRAI	US 1999-434286	A2	19991105	<--			
	WO 2000-US32697	A	20001201	<--			

AB A protocol for prevention of **Alzheimer**'s disease onset is described. The protocol involves stimulating the implicit memory, followed by continuing such stimulation in conjunction with psychol. treatments followed by continuing the stimulation of the implicit memory and, in addn., stimulating the explicit memory. Use of this protocol results in a permanent replacement of undesirable behaviors with desirable ones.

ST behavior chemotherapy **Alzheimer** disease memory stimulation

IT **Alzheimer's disease**
Anti-Alzheimer's agents
Antihypertensives
Behavior
Cardiovascular agents
Cognition enhancers
Human
Hypertension
Memory, biological
Psychotropics
Vasodilators
(behavior chemotherapy for prevention of **Alzheimer**'s disease)

IT Corticosteroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(behavior chemotherapy for prevention of **Alzheimer**'s disease)

IT Rhythm, biological
(circadian, diurnal metab.; behavior chemotherapy for prevention of **Alzheimer**'s disease)

IT Metabolism, animal
(diurnal; behavior chemotherapy for prevention of **Alzheimer**'s disease)

IT Medicine
(psychol., psychol. treatment; behavior chemotherapy for prevention of **Alzheimer**'s disease)

IT Heart, disease
(tachycardia; behavior chemotherapy for prevention of **Alzheimer**'s disease)

IT Adrenoceptor antagonists
(.beta.-; behavior chemotherapy for prevention of **Alzheimer**'s disease)

IT 122-09-8, Phentermine 458-24-2, Fenfluramine 1953-04-4, Galantamine hydrobromide 21829-25-4, Nifedipine **29122-68-7**, Atenolol 59729-33-8, Citalopram 111470-99-6, Amlodipine besylate 120014-06-4, Donepezil 129101-54-8
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(behavior chemotherapy for prevention of **Alzheimer**'s disease)

IT **29122-68-7**, Atenolol
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(behavior chemotherapy for prevention of **Alzheimer**'s disease)

RN 29122-68-7 HCAPLUS

CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



L127 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:429537 HCAPLUS

DN 137:748

TI Method using melatonin inhibitors for the treatment of **neurological** or **neuropsychiatric** disorders

IN Willis, Gregory Lynn
PA Australia
SO U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 285,859.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K031-00
NCL 514001000
CC 1-11 (Pharmacology)
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002068692	A1	20020606	US 2001-971783	20011009 <--
	WO 9815267	A1	19980416	WO 1997-AU661	19971003 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6310085	B1	20011030	US 1999-285859	19990402 <--
PRAI	AU 1996-2745	A	19961004 <--		
	WO 1997-AU661	A2	19971003 <--		
	US 1999-285859	A2	19990402 <--		

AB A method for the treatment and/or prophylaxis of a **neurol**. or **neuropsychiatric** disorder assocd. with altered dopamine function is disclosed which comprises subjecting a patient in need thereof to therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.

ST **neurol neuropsychiatric** disorder treatment melatonin inhibitor; dopamine **neurol** disorder treatment melatonin inhibitor

IT **Brain, disease**
(**Gilles de la Tourette** syndrome; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT **Nervous system**
(**Huntington's chorea**; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT **Mental disorder**
(Pick's disease; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT Disease, animal
(Sundowner's syndrome; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT Stress, animal
(acute stress disorder; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT **Mental disorder**
(agoraphobia; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT **Nervous system**
(akathisia; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT Anorexia
(anorexia cachexia; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT Appetite
(anorexia **nervosa**; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT Ion channel blockers

(calcium; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT **Mental disorder**
(**dementia**; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT **Nervous system**
(disease; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Toxicity
(drug, **neuroleptic**-induced **parkinsonism**; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT **Nervous system**
(dystonia, acute; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)

IT Anxiety
(generalized anxiety disorder; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Disease, animal
(malignant syndrome; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT **Anti-Alzheimer's agents**
Antidepressants
Antiparkinsonian agents
Antipsychotics
Anxiolytics
Diagnosis
Mental disorder
Movement disorders
Nervous system agents
Phototherapy
Psychotropics
Schizophrenia
Wernicke-Korsakoff syndrome
(melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Melatonin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Tranquilizers
(**neuroleptic**-induced **parkinsonism**; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT **Mental disorder**
(obsession-compulsion; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Anxiety
(panic; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Leg
(periodic limb movement syndrome and restless leg syndrome; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Arm
(periodic limb movement syndrome; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT **Mental disorder**
(post-traumatic stress disorder; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Paralysis
(progressive subnuclear palsy; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)

IT Disease, animal
(punch drunk syndrome; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT **Brain, disease**
(**stroke**; melatonin inhibitors for treatment of **neurol**. or **neuropsychiatric** disorder)
IT Pineal gland
(surgical ablation or destruction; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT **Nervous system**
(tardive dyskinesia; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT Multiple sclerosis
(therapeutic agents; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT Anti-ischemic agents
(trans-ischemic attack; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT Adrenoceptor antagonists
(.beta.-; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT 73-31-4, Melatonin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(and precursors and metabolites; melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT **51-61-6**, Dopamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT 525-66-6, Propranolol 9002-79-3, Melanocyte-stimulating hormone **29122-68-7**, Atenolol 115007-18-6, ML-23
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
IT **51-61-6**, Dopamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
RN 51-61-6 HCAPLUS
CN 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) (CA INDEX NAME)



IT **29122-68-7**, Atenolol
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(melatonin inhibitors for treatment of **neurol.** or **neuropsychiatric** disorder)
RN 29122-68-7 HCAPLUS
CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



L127 ANSWER 5 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:368310 HCAPLUS
DN 136:363866
TI Serotonergic compositions and methods for treatment of mild **cognitive** impairment
IN Wurtman, Richard J.; Lee, Robert K. K.
PA Massachusetts Institute of Technology, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-00
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002038142	A2	20020516	WO 2001-US43016	20011108 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030423	A5	20020521	AU 2002-30423	20011108 <--
US 2002173511	A1	20021121	US 2001-986469	20011108 <--
US 2002173549	A1	20021121	US 2001-986470	20011108 <--
PRAI US 2000-246615P	P	20001108 <--		
WO 2001-US43016	W	20011108		

AB A method of treating mild **cognitive** impairment is disclosed. The method comprises administering an effective amt. of a serotonergic agent, including, but not limited to, dexnorfenfluramine. The agent can be any serotonergic agonist, partial agonist, serotonin reuptake inhibitor, or combinations of these agents. The treatment method also encompasses combinations of serotonergic agents and nonsteroidal antiinflammatory agents. The treatment method may also delay the onset of mild **cognitive** impairment, **dementia**, or both.
ST mild **cognitive** impairment **dementia** serotoninergic agent pharmaceutical; serotonin reuptake inhibitor mild **cognitive** impairment; dexnorfenfluramine mild **cognitive** impairment; serotoninergic agent NSAID mild **cognitive** impairment
IT **Astrocyte**
(APP overexpression inhibition in; serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT 5-HT agonists
(and partial agonists; serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT Drug delivery systems
(enteric; serotonergic compns. and methods for treatment of mild

cognitive impairment)
IT Drug delivery systems
(oral; serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT Drug delivery systems
(parenterals; serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT 5-HT antagonists
Cognition enhancers
Drug delivery systems
(serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT Cerebrospinal fluid
(sol. **amyloid** precursor protein in; serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT **Amyloid precursor proteins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sol., secretion-stimulating agent; serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT Drug delivery systems
(topical; serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT 50-67-9, Serotonin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reuptake inhibitors; serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT 66-83-1 73-22-3, Tryptophan, biological studies 93-65-2, MCPP **102-02-3**, Phenylbiguanide 153-98-0, Serotonin hydrochloride 303-49-1, Clomipramine 304-52-9, .alpha.-Methyl-5-hydroxytryptamine 458-24-2, Fenfluramine 971-74-4, Serotonin creatinine sulfate 1054-88-2, Spiroxatrine 1152-76-7, Mescaline sulfate 1814-64-8, LY-165163 2113-05-5 2170-58-3 2315-02-8, Oxymetazoline hydrochloride 2963-79-3, Bufotenine monooxalate 3036-16-6, Serotonin oxalate 3239-44-9, Dexfenfluramine 4350-09-8, 5-Hydroxy tryptophan 4774-24-7, Quipazine 5464-78-8, 1-(2-Methoxyphenyl)piperazine hydrochloride 5787-02-0 13078-15-4, 1-(3-Chlorophenyl)piperazine hydrochloride 15232-63-0 15532-75-9, TFMPP 17286-40-7 19036-73-8, Dexnorfenfluramine 21102-95-4, BMY 7378 24973-25-9 28614-26-8, N-Methylquipazine 29705-96-2 **34661-85-3**, 5-Methylurapidil 36505-84-7, Buspirone 42203-78-1 48144-44-1, m-Chlorophenylbiguanide 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 57477-39-1 59729-33-8, Citalopram 61869-08-7, Paroxetine 64022-27-1, MK 212 64887-14-5, Urapidil hydrochloride 74885-09-9, 5-Carboxamidotryptamine 74885-25-9 76135-31-4 77145-61-0 77372-73-7, 6-Nitroquipazine 78095-20-2 78263-90-8, 2-Methyl-5-hydroxytryptamine 78263-91-9 78950-78-4 79617-96-2, Sertraline 80300-09-0 82864-02-6 82900-57-0, BP-554 98330-05-3, Anpirtoline 99665-05-1 103628-46-2, Sumatriptan 107008-28-6, RU 24969 **109028-10-6**, CGS-12066B 109140-25-2 124756-23-6, MDL 73005EF 127126-20-9 127792-75-0, CP 93129 134296-40-5 137403-12-4 141196-99-8, SC 53116 141510-98-7 143137-35-3, RS 56812 148868-55-7 150323-78-7, Quipazine dimaleate 155106-73-3, 2-[1-(4-Piperonyl)piperazinyl]benzothiazole 157798-12-4, 5-Nonyloxytryptamine 157798-13-5 159559-70-3 160521-72-2 160845-95-4 168986-60-5, RS 67333 169675-08-5 171205-17-7 182563-09-3 185259-85-2, GR 46611 187665-60-7
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(serotonergic compns. and methods for treatment of mild **cognitive** impairment)
IT **102-02-3**, Phenylbiguanide **34661-85-3**, 5-Methylurapidil **109028-10-6**, CGS-12066B
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(serotonergic compns. and methods for treatment of mild **cognitive** impairment)

RN 102-02-3 HCAPLUS
CN Imidodicarbonimidic diamide, N-phenyl- (9CI) (CA INDEX NAME)



RN 34661-85-3 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3,5-trimethyl- (9CI) (CA INDEX NAME)



RN 109028-10-6 HCAPLUS
CN Pyrrolo[1,2-a]quinoxaline, 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 109028-09-3
CMF C17 H17 F3 N4



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L127 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:314758 HCAPLUS
DN 136:319416
TI Combination of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of **cognitive** disorders
IN Villalobos, Anabella; Cassella, James Vincent; Rajachandran, Lavanya
PA Pfizer Products Inc., USA; Neurogen Corporation
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-00
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032412	A2	20020425	WO 2001-IB1934	20011015 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002151591	A1	20021017	US 2001-976347	20011012 <--
	AU 2001094117	A5	20020429	AU 2001-94117	20011015 <--
PRAI	US 2000-241145P	P	20001017 <--		
	WO 2001-IB1934	W	20011015		

OS MARPAT 136:319416
GI



AB This invention provides a compn. for treating a **cognitive** disorder, which comprises an acetylcholinesterase, and a GABAA inverse agonist selected from a compd. (I, where X = e.g., H, halo, Ph, naphthyl, pyridinyl; Y = e.g.,C1-8 alkyl, carbocycle). Thus, aricept and a GABAA inverse agonist (e.g., N-benzyl-6-ethoxy-4-oxo-1,4-tetrahydro-1,5-naphthyridine-3-carboxamide), when coadministered. interact to attenuate scopolamine-induced deficits in the spatial water maze.
ST acetylcholinesterase inhibitor GABAA agonist **cognitive** enhancer;

aricept tetrahydronaphthyridinecarboxamide **cognitive** enhancer

IT GABA agonists
(GABAA; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT **Mental disorder**
(attention deficit disorder; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT **Mental disorder**
(**cognitive**; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT **Anti-Alzheimer's agents**
Antiparkinsonian agents
Cognition enhancers
Down's syndrome
Drug delivery systems
Memory, biological
Psychotropics
(combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT ~~Mental disorder~~
(**dementia**, vascular; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT **Cognition**
(disorder; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT Drug delivery systems
(prodrugs; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT **Brain, disease**
(**stroke**; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT Drug interactions
(synergistic; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT **Brain, disease**
(trauma; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for ~~treatment of cognitive~~ disorders)

IT 52-68-6, Metrifonate, **57-47-6**, Physostigmine 321-64-2, Tacrine 357-70-0, Galantamine ~~102518-79-6, Huperzine A~~ 120011-70-3, Aricept 123441-03-2, Rivastigmine 145508-78-7, Icopezil 220860-40-2 220860-45-7 220860-47-9 220860-48-0 220860-50-4 220860-52-6 220860-56-0 220860-58-2 220860-59-3 220860-60-6 220860-62-8 220860-64-0 220860-65-1 220860-66-2 220860-67-3 220860-68-4 220860-70-8 220860-72-0 220860-74-2 220860-75-3 220860-81-1 220860-90-2 220860-92-4 220860-93-5 220860-95-7 220861-17-6 304680-79-3 415678-14-7 415678-15-8
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT 9000-81-1, Acetylcholinesterase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

IT **57-47-6**, Physostigmine
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of **cognitive** disorders)

RN 57-47-6 HCAPLUS

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L127 ANSWER 7 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:241334 HCAPLUS
DN 136:257275
TI Method and composition for modulating **amyloidosis**
IN Reiner, Peter B.; Lam, Fred Chiu-Lai
PA Can.
SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 67,523, abandoned.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM C12Q001-00
ICS G01N033-53; A61K038-00; G01N033-00; C12N009-00; C07K005-00; C07K007-00; C07K016-00; C07K017-00; A61K038-12
NCL 514011000
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002037843	A1	20020328	US 1998-177413	19981023 <--
	US 6514686	B2	20030204		
	WO 2000024390	A1	20000504	WO 1999-US23885	19991014 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1123090	A1	20010816	EP 1999-954894	19991014 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002528411	T2	20020903	JP 2000-578000	19991014 <--
PRAI	US 1997-847616	B2	19970428 <--		
	US 1998-67523	B2	19980428 <--		
	US 1998-177413	A2	19981023 <--		
	WO 1999-US23885	W	19991014 <--		

AB Methods for modulating **amyloid** deposition in a subject are

described. An effective amt. of at least one ATP binding cassette (ABC) transporter blocker is administered to a subject, such that modulation of **amyloid** deposition occurs. Methods also include administering and effective amt. of at least one ABC transporter blocker, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state assocd. with **amyloidosis** is treated. Packaged pharmaceutical compns. for treating **amyloidosis** are described. The package includes a container for holding an effective amt. of a pharmaceutical compn. and instructions for using the pharmaceutical compn. for treatment of **amyloidosis**. The pharmaceutical compn. includes at least one ABC blocker for modulating **amyloid** deposition in a subject. Methods for identifying agents which modulate **amyloid** deposition in a subject are also described. An effective amt. of at least one ATP binding cassette (ABC) transporter blocker is administered to an organism, such that modulation of **amyloid** deposition occurs.

ST modulating **amyloidosis**; **amyloid** deposition modulation
ATP binding cassette transporter blocker

IT **Brain**
(ABC transporter blockade in; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT EST (expressed sequence tag)
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ABC transporter blocker-encoding; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ABC1, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ABC2, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ABC3, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ABC7, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ABC8, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **Alzheimer's disease**
Amyloidosis
Anti-Alzheimer's agents
Bilayer membranes
Cell membrane
Drug screening
Human
Liposomes
Membrane, biological
Multidrug resistance
(ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ATP binding cassette (ABC) transporter, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MDR1, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MRP4, inhibitors; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MRP5, inhibitors; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT P-glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **Amyloid precursor proteins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cleavage of; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **Amyloid**
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(deposition of; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Biological transport
(efflux, pump; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Labels
(for drug packaging; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Packaging materials
(for drugs; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Head
(injury; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mdr3, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Blood vessel
(microvessel, of brain, ABC transporter blockade in; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Protein degradation
(of **amyloid** precursor protein; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phospholipid-transporting, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **Brain, disease**
(**stroke**; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **Amyloid**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.-; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 51-55-8, Atropine, biological studies 52-53-9, Verapamil 54-05-7, Chloroquine **57-47-6**, Physostigmine 61-54-1, Tryptamine 65-61-2, Acridine orange 83-89-6, Quinacrine 90-34-6, Primaquine 117-89-5, Trifluoperazine 130-95-0, Quinine 146-48-5, Yohimbine

260-94-6, Acridine 483-10-3, Corynanthine 485-71-2, Cinchonidine 525-66-6, Propranolol 10540-29-1, Tamoxifen 59865-13-3, Cyclosporin 59865-15-5, Cyclosporin A, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)octanoic acid]- 64657-18-7, 1,9-Dideoxyforskolin 66575-29-9, Forskolin 84371-65-3, RU-486 92302-55-1, Benzeneacetonitrile, 3,4-dimethoxy-.alpha.-[3-[[2-(3-methoxyphenyl)ethyl]methylamino]propyl]-.alpha.-(1-methylethyl)- 104987-11-3, FK-506 119666-09-0, AHC-52 121584-18-7, PSC-833 129716-45-6, MS-073 140945-01-3, S9788 143664-11-3, GF120918 158681-49-3, MS-209 159997-94-1, VX-710 190454-58-1, VX-853
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT 123955-65-7, RU 49953
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RU 49953; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT 180422-22-4, XR 9051
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(XR 9051; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT 56-65-5, 5'-ATP, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cassette binding; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **57-47-6**, Physostigmine
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

RN 57-47-6 HCAPLUS
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L127 ANSWER 8 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN **2002:10812** HCAPLUS
DN **136:79718**
TI Rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening
IN **Bamdad, Cynthia C.; Bamdad, R. Shoshana**

PA **Minerva Biotechnologies Corporation, USA**
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G01N033-68
CC 1-1 (Pharmacology)
Section cross-reference(s): 14
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002001230	A2	20020103	WO 2001-US20232	20010625
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001070157	A5	20020108	AU 2001-70157	20010625
PRAI	US 2000-602689	A	20000623		
	US 2000-631818	A	20000803		
	WO 2001-US20232	W	20010625		

AB Methods, assays, and components are described in which biol. samples can be rapidly and sensitively analyzed for the presence of species assocd. with **neurodegenerative** disease. Techniques and components are provided for diagnosis of disease, as well as for screening of candidate drugs for treatment of **neurodegenerative** disease. The techniques are simple, extremely sensitive, and utilize readily-available components. Binding species, capable of binding a **neurodegenerative** disease **aggregate**-forming or **aggregate**-forming species, are fastened to surfaces of electrodes and surfaces of particles, or provided free in soln., to bind **aggregate**-forming species and/or be involved in **aggregation.**

ST aberrant protein fibril **aggregation** colloid; drug screening **neurodegenerative** disease kit

IT **Brain, disease**
Prion diseases
(**Creutzfeldt-Jakob**; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT **Prion proteins**
RL: DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(PrPSc; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT Voltammetry
(a.c.; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT Spheres
(beads; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT **Prion proteins**
RL: DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(bovine spongiform encephalopathy; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in

neurodegenerative disease diagnosis and drug screening)
IT Proteins
RL: DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(complexes; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)
IT **Nervous system**
(degeneration; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)
IT Self-assembled monolayers
(electroactive; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)
IT Immunoassay
(enzyme-linked immunosorbent assay; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)
IT Enzymes, biological studies
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(inhibitors, capsase; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)
IT Carboxyl group
(ionized; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)
IT **Aggregation**
Alzheimer's disease
Animal
Animal cell
Blood analysis
Cerebrospinal fluid
Colloids
Diagnosis
Drug screening
Feed
Fibril
High throughput screening
Human
Immobilization, molecular
Livestock
Magnetic particles
Microtiter plates
Milk
Molecular association
Molecular recognition
Parkinson's disease
Protein sequences
Test kits
Transplant and Transplantation
UV and visible spectroscopy
(rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)
IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT p53 (protein)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT Metallocenes
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT DNA
RL: DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT Nucleic acids
Oligonucleotides
Proteins
RL: PRP (Properties)
(rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT Antibodies
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT **Brain, disease**
(**spongiform encephalopathy**, transmissible; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT Sensors
(surface plasmon resonance chip; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT Transferrins
RL: BSU (Biological study, unclassified); CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); BIOL (Biological study); PROC (Process)
(.tau.-transferrins; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT **Amyloid**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(.beta.-, C-terminal fragment; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis and drug screening)

IT **Amyloid**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(.beta.-; rapid and sensitive detection of aberrant protein(fibril) **aggregation** in **neurodegenerative** disease diagnosis

and drug screening)
IT 167396-02-3 286411-43-6 286411-44-7 286411-46-9 286411-47-0
286411-48-1
RL: PRP (Properties)
(Unclaimed; rapid and sensitive detection of aberrant protein(fibril)
aggregation in **neurodegenerative** disease diagnosis
and drug screening)
IT 7732-18-5, Water, biological studies
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(rapid and sensitive detection of aberrant protein(fibril)
aggregation in **neurodegenerative** disease diagnosis
and drug screening)
IT 58-85-5, 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-,
(3aS,4S,6aR)- 70-18-8, Glycine, L-.gamma.-glutamyl-L-cysteinyl-,
properties 102-54-5, Ferrocene 139-13-9, Glycine, N,N-
bis(carboxymethyl)- 573-58-0, 1-Naphthalenesulfonic acid,
3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis4-amino-, disodium salt
2390-54-7, Benzothiazolium, 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-,
chloride 6066-82-6, 2,5-Pyrrolidinedione, 1-hydroxy- 9001-78-9,
Phosphatase, alkaline 9013-20-1, Streptavidin 10487-90-8, Phenol,
2,2'-[(6,6'-dimethyl[1,1'-biphenyl]-2,2'-diyl)bis(nitrilomethylidyne)]bis-
64691-70-9, Pyridine, 2,2'-[1,2-ethanediylbis(thio-2,1-ethanediyl)]bis-
RL: CPS (Chemical process); PEP (Physical, engineering or chemical
process); PRP (Properties); PROC (Process)
(rapid and sensitive detection of aberrant protein(fibril)
aggregation in **neurodegenerative** disease diagnosis
and drug screening)
IT 7440-57-5, Gold, properties
RL: DEV (Device component use); PRP (Properties); USES (Uses)
(rapid and sensitive detection of aberrant protein(fibril)
aggregation in **neurodegenerative** disease diagnosis
and drug screening)
IT 78990-62-2, Calpain 158736-49-3, .beta.-Secretase 338454-52-7,
.gamma.-Secretase
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological
study)
(rapid and sensitive detection of aberrant protein(fibril)
aggregation in **neurodegenerative** disease diagnosis
and drug screening)

L127 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:798758 HCAPLUS
DN 135:339282
TI Nicotine receptor partial agonist, cholinesterase inhibitor, and
estrogenic agent composition for treatment of diseases of
cognitive dysfunction in a mammal
IN Coe, Jotham Wadsworth; Sands, Steven Bradley; Harrigan, Edmund Patrick;
O'Neill, Brian Thomas; Watsky, Eric Jacob
PA USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K031-44
ICS A01N043-42
NCL 514299000
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001036949	A1	20011101	US 2001-760966	20010116 <--

WO 2001085145 A2 20011115 WO 2001-IB681 20010424 <--
WO 2001085145 A3 20020613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1280554 A2 20030205 EP 2001-921733 20010424 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2000-202799P P 20000509 <--
WO 2001-IB681 W 20010424

AB A pharmaceutical compn. and method of treatment of diseases of **cognitive** dysfunction in a mammal comprising administration of a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof; and an acetylcholinesterase inhibitor, butylcholinesterase inhibitor, an estrogenic agent, selective estrogen receptor modulator or muscarinic agonist or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and acetylcholinesterase inhibitor, butylcholinesterase inhibitor, estrogen, selective estrogen receptor modulator or muscarinic agonist are present in amts. that render the compn. effective enhancing **cognition** or in the treatment of diseases of **cognitive** dysfunction including but not limited to **Alzheimer**'s Disease, mild **cognitive** impairment, age-related **cognitive** decline, vascular **dementia**, **Parkinson**'s disease **dementia**, **Huntington**'s Disease, Stroke, TBI, AIDS assocd. **dementia** and schizophrenia. The method of using these compns. is also disclosed.

ST **cognitive** dysfunction treatment compn; nicotinic agonist **cognitive** dysfunction treatment compn; cholinesterase inhibitor **cognitive** dysfunction treatment compn; estrogen **cognitive** dysfunction treatment compn

IT **Nervous system**
(**Huntington's chorea**; nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT **Mental disorder**
(**cognitive**; nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT **Mental disorder**
(**dementia**; nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT **Cognition**
(disorder; nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT **Alzheimer's disease**
Muscarinic agonists
Nicotinic agonists
Parkinson's disease
Schizophrenia
(nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT **Brain, disease**
(**stroke**; nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT 9000-81-1, Acetylcholinesterase 9001-08-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT 50-28-2, Estradiol, biological studies 52-68-6, Metrifonate
57-47-6, Physostigmine 59-99-4, Neostigmine 63-75-2, Arecoline
70-22-4, Oxotremorine 92-13-7, Pilocarpine 101-26-8, Mestinon
321-64-2, Tacrine 357-70-0, Galanthamine 469-22-7, Eseroline
10540-29-1, Tamoxifen 69718-72-5 82413-20-5, Droloxifene 84449-90-1,
Raloxifene 102518-79-6, Huperzine A 120011-70-3, Aricept
123441-03-2, Rivastigmine 131986-45-3, Xanomeline 132236-18-1,
Zifrosilone 139314-01-5, Quilostigmine 139886-32-1, Milameline
145209-30-9, Tolserine 145209-39-8, Cymserine 145209-50-3,
Thiatolserine 145209-51-4, Thiacymserine 145508-78-7, Icopezil
159912-53-5, Sabcomeline 180916-16-9, Lasofoxifene 207391-08-0
207391-10-4 207391-12-6 207391-15-9 207391-18-2 207391-21-7
207391-24-0 207391-27-3 207391-28-4 207391-29-5 207391-34-2
207391-36-4 207391-37-5 207391-38-6 207391-40-0 207391-41-1
207391-42-2 207391-44-4 207391-63-7 207391-64-8 207391-65-9
207391-67-1 207391-74-0 230615-75-5 248275-68-5 248275-79-8
248275-81-2 248275-95-8 248276-19-9 249296-44-4 287973-23-3
287973-26-6 287973-27-7 328055-76-1 328055-77-2 328055-78-3
328055-79-4 328055-80-7 328055-81-8 328055-83-0 328055-84-1
328055-85-2 328055-86-3 328055-87-4 328055-88-5 328055-89-6
328055-90-9 328055-92-1 328055-94-3 328055-95-4 328055-96-5
328055-97-6 328055-98-7 328055-99-8 328056-00-4 328056-01-5
328056-02-6 328056-03-7 328056-04-8 328056-05-9 328056-06-0
328056-07-1 328056-08-2 328056-09-3 328056-10-6 328056-11-7
328056-16-2 328056-17-3 328056-18-4 328056-19-5 328056-20-8
328056-21-9 328056-22-0 328056-23-1 328056-24-2 328056-25-3
328056-26-4 328056-27-5 328056-28-6 328056-29-7 328056-30-0
328056-66-2 357424-19-2 357424-20-5 371238-38-9 371238-39-0
371238-40-3 371238-41-4
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

IT **57-47-6**, Physostigmine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of **cognitive** dysfunction in a mammal)

RN 57-47-6 HCAPLUS
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L127 ANSWER 10 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:792336 HCAPLUS
DN 135:339274
TI Method for the treatment of **neurological** or **neuropsychiatric** disorders with melatonin antagonists
IN Willis, Gregory Lynn
PA Clarence Pty Ltd., Australia
SO U.S., 31 pp., Cont.-in-part of Appl. No. PCT/AU97/00661
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K031-405
NCL 514415000
CC 1-11 (Pharmacology)
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6310085	B1	20011030	US 1999-285859	19990402	<--
	WO 9815267	A1	19980416	WO 1997-AU661	19971003	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	WO 2000059504	A1	20001012	WO 2000-AU275	20000331	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	BR 2000009524	A	20020219	BR 2000-9524	20000331	<--
	EP 1189613	A1	20020327	EP 2000-912271	20000331	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	JP 2002541105	T2	20021203	JP 2000-609068	20000331	<--
	EE 200100511	A	20021216	EE 2001-511	20000331	<--
	NO 2001004674	A	20010926	NO 2001-4674	20010926	<--
	US 2002068692	A1	20020606	US 2001-971783	20011009	<--

PRAI WO 1997-AU661 A2 19971003 <--
AU 1996-2745 A 19961004 <--
US 1999-285859 A 19990402 <--
WO 2000-AU275 W 20000331 <--

GI



I

AB A method for the treatment and/or prophylaxis of a **neurol**. or **neuropsychiatric** disorder assocd. with altered dopamine function comprises administering melatonin antagonists I (X = NO2, N3; Y = H, I) to a patient in need thereof. I (X = NO2; Y = H) (ML-23) prevented the development of severe motor impairment and severe body wt. loss typically exhibited by **neurotoxin** 6-hydroxydopamine-treated rats.

ST **neurol** disorder **neuropsychiatric** disorder treatment melatonin antagonist

IT **Brain, disease**
(**Gilles de la Tourette** syndrome; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)

IT **Nervous system**
(**Huntington's chorea**; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists)

IT **Mental disorder**
(Korsakow's syndrome; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)

IT **Mental disorder**
(Pick's disease; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists)

IT **Mental disorder**
(Punch drunk syndrome; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists)

IT **Mental disorder**
(Sundowner's syndrome; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)

IT Stress, animal
(acute; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)

IT **Mental disorder**
(agoraphobia; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists)

IT Appetite
(anorexia **nervosa**; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists)

IT Cachexia
(anorexia; method for treatment of **neurol**. or **neuropsychiatric** disorders with melatonin antagonists)

IT Anorexia

(cachexia; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)
IT Ion channel blockers
(calcium; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with a calcium channel blocker)
IT **Mental disorder**
(**dementia**; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)
IT **Mental disorder**
(depression, anxiety disorders due to; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT **Nervous system**
(disease, malignant syndrome; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT **Nervous system**
(dystonia, acute; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT **Brain, disease**
(**ischemia, transient**; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)
IT **Anti-Alzheimer's agents**
Antiparkinsonian agents
Anxiolytics
Movement disorders
Multiple sclerosis
(method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT **Nervous** system agents
Phototherapy
Psychotropics
Schizophrenia
Wernicke-Korsakoff syndrome
(method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)
IT Pineal gland
(method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with surgical ablation or destruction of the pineal gland)
IT **Nervous system**
(multiple system atrophy; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT **Mental disorder**
(obsession-compulsion; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT Anxiety
(panic disorder; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT Movement disorders
(periodic limb movement disorders; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)
IT **Mental disorder**
(post-traumatic stress disorder; method for treatment of **neurol** . or **neuropsychiatric** disorders with melatonin antagonists)
IT **Mental disorder**
(post-traumatic stress disorder; method for treatment of **neurol** . or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)

IT Paralysis
(progressive subnuclear; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)
IT Movement disorders
(restless leg syndrome; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with light therapy)
IT **Brain, disease**
(**stroke**; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT **Nervous system**
(tardive dyskinesia; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT Adrenoceptor antagonists
(.beta.-; method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with a .beta.-adrenergic antagonist)
IT 73-31-4, Melatonin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; **neurol.** or **neuropsychiatric** disorders assocd. with altered dopamine function treatment with melatonin antagonists)
IT 152302-33-5, S-20928
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT 115007-18-6, ML-23
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists)
IT 9002-79-3, Melanocyte stimulating hormone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with MSH)
IT **29122-68-7**, Atenolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with a drug that alters dopamine function)
IT **51-61-6**, Dopamine, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**neurol.** or **neuropsychiatric** disorders assocd. with altered dopamine function treatment with melatonin antagonists)
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Alder; Pychopharmacology Bulletin 1991, V27(2), P107
(2) Anon; EP 0146113 1985 HCAPLUS
(3) Anon; WO 9529173 1995 HCAPLUS
(4) Artmenko, A; Arch Neurol 1996, V44
(5) Chuprikov; US 5137018 1992
(6) Depreux; US 5552418 1996 HCAPLUS
(7) Dubocovich; US 5093352 1992 HCAPLUS
(8) Dubocovich; US 5283343 1994 HCAPLUS
(9) Horn; US 5071875 1991 HCAPLUS
(10) Koller; Arch Neurol 1987, V44, P921 MEDLINE

(11) Martindale; The Extra Pharmacopoeia 28th Edition 1982, P1337
(12) Merk Research Laboratories; The Merk Manual of Diagnosis and Therapy, 16th Edition 1992, P1499
(13) Miles; Biol Psychiatry 1988, V23, P405 HCAPLUS
(14) Sandyk, R; Intern J Neuroscience 1992, V66, P1 MEDLINE
(15) Sandyk, R; Intern J Neuroscience 1993, V68, P85 MEDLINE
(16) Searfoss; US 5046494 1991
(17) Sherer; Neurosci Lett 1985, V58(3), P277 MEDLINE
(18) Wilbur; Prog Neuro-Psychoparmacol and Biol Psychiat 1988, V12, P849 MEDLINE
(19) Yous; US 5616614 1997 HCAPLUS
(20) Zisapel; US 4880826 1989 HCAPLUS

IT **29122-68-7**, Atenolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(method for treatment of **neurol.** or **neuropsychiatric** disorders with melatonin antagonists in combination with a drug that alters dopamine function)
RN 29122-68-7 HCAPLUS
CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



IT **51-61-6**, Dopamine, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**neurol.** or **neuropsychiatric** disorders assocd. with altered dopamine function treatment with melatonin antagonists)
RN 51-61-6 HCAPLUS
CN 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) (CA INDEX NAME)



L127 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN **2001:780668** HCAPLUS
DN **135:335153**
TI Treatment of **neurodegenerative** disease
IN **Bamdad, R. Shoshanna; Bamdad, Cynthia C.**
PA **Minerva Biotechnologies Corporation, USA**
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-00
CC 63-6 (**Pharmaceuticals**)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001078709	A2	20011025	WO 2001-US12484	20010412 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	US 2003060487	A1	20030327	US 2001-835099	20010412 <--
PRAI	US 2000-196497P	P	20000412 <--		
	US 2000-214221P	P	20000623 <--		
	US 2000-248890P	P	20001115 <--		

OS MARPAT 135:335153

AB The invention relates to treatments for peptide **aggregation** assocd. with disease states such as **neurodegenerative** disease, particularly physiol. assocd. with **Alzheimer**'s Disease, and non-**neurodegenerative** disease **aggregation**. Other aspects of the invention also provides a variety of novel assays for screening candidate drugs. Yet another aspects of the present invention also provides a series of compns. useful for treatment of **neurol**. disease as detd. from these assays. These compns. can be packaged in kits. Other aspects of the invention also relate to the use of these compns. for the treatment and/or prevention of patients susceptible to or exhibiting of a disease characteristic of fibril formation or aberrant protein **aggregation**. Examples are given for monitoring drug activity as a function of time for drug profiling and cell-based screening assay for candidate drugs for affecting **aggregate** formation at a variety of stages of biochem. progression.

ST **neurodegenerative** disease treatment compn

IT **Brain, disease**
Prion diseases
(**Creutzfeldt-Jakob**; treatment of **neurodegenerative** disease)

IT **Nervous system**
(**Huntington's chorea**; treatment of **neurodegenerative** disease)

IT **Nervous system**
(degeneration; treatment of **neurodegenerative** disease)

IT **Mental disorder**
(**dementia**; treatment of **neurodegenerative** disease)

IT **Amyloidosis**
(familial **amyloidotic polyneuropathy**, type IV; treatment of **neurodegenerative** disease)

IT **Brain, disease**
Prion diseases
(**fatal familial insomnia**; treatment of **neurodegenerative** disease)

IT **Insomnia**
(**fatal familial**; treatment of **neurodegenerative** disease)

IT **Brain, disease**
Prion diseases
(**kuru**; treatment of **neurodegenerative** disease)

IT **Nerve, disease**
(**polyneuropathy**; treatment of **neurodegenerative** disease)

IT **Aggregates**

(protein, formation of; treatment of **neurodegenerative** disease)

IT **Amyloidosis**
(**senile**; treatment of **neurodegenerative** disease)

IT **Brain, disease**
(**spongiform encephalopathy**; treatment of **neurodegenerative** disease)

IT **Brain, disease**
(**spongiform myeloencephalopathy**; treatment of **neurodegenerative** disease)

IT **Brain, disease**
(**stroke**; treatment of **neurodegenerative** disease)

IT **Alzheimer's disease**
Parkinson's disease
Sickle cell anemia
(treatment of **neurodegenerative** disease)

IT **Diabetes mellitus**
(type II; treatment of **neurodegenerative** disease)

IT **50-33-9**, Phenylbutazone, biological studies **52-01-7**, Spironolactone **55-10-7**, Vanillylmandelic acid **57-47-6**, (-)-Physostigmine **61-76-7**, Phenylephrine hydrochloride **65-28-1**, Phentolamine mesylate **65-29-2**, Gallamine triethiodide **80-77-3**, Chlormezanone **102-02-3**, 1-Phenylbiguanide **125-33-7**, Primidone **130-61-0**, Thioridazine hydrochloride **136-47-0**, Tetracaine hydrochloride **146-56-5**, FLuphenazine dihydrochloride **300-08-3**, Arecoline hydrobromide **504-24-5**, 4-Aminopyridine **518-28-5**, Podophyllotoxin **581-88-4**, Debrisoquin sulfate **614-39-1**, Procainamide hydrochloride **770-05-8**, Octopamine hydrochloride **1011-74-1**, Normetanephrine hydrochloride **1069-66-5**, Sodium valproate **1867-73-8** **1952-15-4** **2145-56-4** **4789-68-8**, Octoclothepin maleate **13153-27-0**, S-(4-Nitrobenzyl)-6-thioguanosine **13523-86-9**, Pindolol **15307-79-6**, Diclofenac sodium **15676-16-1**, Sulpiride **16709-43-6**, cis-Dioxolane **17560-51-9**, Metolazone **27833-64-3**, Loxapine succinate **29122-68-7**, Atenolol **30817-59-5**, Oxotremorine methiodide **34661-85-3**, 5-Methylurapidil **35873-49-5**, 8-Cyclopentyl-1,3-dimethylxanthine **38048-32-7** **41094-88-6**, Tracazolate **51481-61-9**, Cimetidine **53296-10-9**, 2-Phenylaminoadenosine **56715-13-0**, **64710-63-0** **75614-89-0** **89805-39-0** **93379-54-5**, S-Atenolol **96850-13-4** **100069-68-9** **104809-20-3** **109028-10-6**, CGS-12066B **123064-80-2** **127299-93-8** **147416-96-4**, Telenzepine dihydrochloride **148440-81-7** **149981-25-9** **153587-01-0** **175615-76-6** **192575-19-2** **369647-58-5** **369647-59-6** **369647-60-9**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **neurodegenerative** disease)

IT **50-33-9**, Phenylbutazone, biological studies **52-01-7**, Spironolactone **55-10-7**, Vanillylmandelic acid **57-47-6**, (-)-Physostigmine **61-76-7**, Phenylephrine hydrochloride **65-28-1**, Phentolamine mesylate **65-29-2**, Gallamine triethiodide **80-77-3**, Chlormezanone **102-02-3**, 1-Phenylbiguanide **125-33-7**, Primidone **130-61-0**, Thioridazine hydrochloride **136-47-0**, Tetracaine hydrochloride **146-56-5**, FLuphenazine dihydrochloride **300-08-3**, Arecoline hydrobromide **504-24-5**, 4-Aminopyridine **518-28-5**, Podophyllotoxin **581-88-4**, Debrisoquin sulfate **614-39-1**, Procainamide hydrochloride **770-05-8**, Octopamine hydrochloride **1011-74-1**, Normetanephrine hydrochloride **1069-66-5**, Sodium valproate **1867-73-8**

1952-15-4 2145-56-4 4789-68-8, Octoclothepin maleate **13153-27-0**, S-(4-Nitrobenzyl)-6-thioguanosine **13523-86-9**, Pindolol **15307-79-6**, Diclofenac sodium **15676-16-1**, Sulpiride **16709-43-6**, cis-Dioxolane **17560-51-9**, Metolazone **27833-64-3**, Loxapine succinate **29122-68-7**, Atenolol **30817-59-5**, Oxotremorine methiodide **34661-85-3**, 5-Methylurapidil **35873-49-5**, 8-Cyclopentyl-1,3-dimethylxanthine **38048-32-7 41094-88-6**, Tracazolate **51481-61-9**, Cimetidine **53296-10-9**, 2-Phenylaminoadenosine **56715-13-0 64710-63-0 75614-89-0 89805-39-0 93379-54-5**, S-Atenolol **96850-13-4 100069-68-9 104809-20-3 109028-10-6**, CGS-12066B **123064-80-2 127299-93-8 147416-96-4**, Telenzepine dihydrochloride **148440-81-7 149981-25-9 153587-01-0 175615-76-6 192575-19-2 369647-58-5 369647-59-6 369647-60-9**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **neurodegenerative** disease)

RN 50-33-9 HCAPLUS
CN 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 52-01-7 HCAPLUS
CN Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, .gamma.-lactone, (7.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 55-10-7 HCAPLUS
CN Benzeneacetic acid, .alpha.,4-dihydroxy-3-methoxy- (9CI) (CA INDEX NAME)



RN 57-47-6 HCAPLUS
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 61-76-7 HCAPLUS
CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 65-28-1 HCAPLUS
CN Phenol, 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 75-75-2
CMF C H4 O3 S



CM 2

CRN 50-60-2
CMF C17 H19 N3 O



RN 65-29-2 HCAPLUS
CN Ethanaminium, 2,2',2''-[1,2,3-benzenetriyltris(oxy)]tris[N,N,N-triethyl-, triiodide (9CI) (CA INDEX NAME)



●3 I⁻

RN 80-77-3 HCAPLUS
CN 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 102-02-3 HCAPLUS
CN Imidodicarbonimidic diamide, N-phenyl- (9CI) (CA INDEX NAME)



RN 125-33-7 HCAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 130-61-0 HCAPLUS
CN 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 136-47-0 HCAPLUS
CN Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 146-56-5 HCAPLUS

CN 1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 300-08-3 HCAPLUS
CN 3-Pyridinecarboxylic acid, 1,2,5,6-tetrahydro-1-methyl-, methyl ester, hydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 504-24-5 HCAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)



RN 518-28-5 HCAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R,5aR,8aR,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 581-88-4 HCAPLUS
CN 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 1131-64-2
CMF C10 H13 N3



RN 614-39-1 HCAPLUS
CN Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 770-05-8 HCAPLUS
CN Benzenemethanol, .alpha.-(aminomethyl)-4-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 1011-74-1 HCAPLUS
CN Benzenemethanol, .alpha.-(aminomethyl)-4-hydroxy-3-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 1069-66-5 HCAPLUS
CN Pentanoic acid, 2-propyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 1867-73-8 HCAPLUS
CN Adenosine, N-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1952-15-4 HCAPLUS
CN Piperidinium, 4-[(diphenylacetyl)oxy]-1,1-dimethyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 2145-56-4 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 4789-68-8 HCAPLUS
CN Piperazine, 1-(8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 13448-22-1
CMF C19 H21 Cl N2 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 13153-27-0 HCAPLUS
CN Guanosine, 6-S-[(4-nitrophenyl)methyl]-6-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 13523-86-9 HCAPLUS
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 15307-79-6 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 15676-16-1 HCAPLUS
CN Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 16709-43-6 HCAPLUS
CN 1,3-Dioxolane-4-methanaminium, N,N,N,2-tetramethyl-, iodide, (2R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 17560-51-9 HCAPLUS
CN 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 27833-64-3 HCAPLUS
CN Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 1977-10-2
CMF C18 H18 Cl N3 O



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 29122-68-7 HCAPLUS
CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 30817-59-5 HCAPLUS

CN Pyrrolidinium, 1-methyl-1-[4-(2-oxo-1-pyrrolidinyl)-2-butynyl]-, iodide (8CI, 9CI) (CA INDEX NAME)



RN 34661-85-3 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3,5-trimethyl- (9CI) (CA INDEX NAME)



RN 35873-49-5 HCAPLUS
CN 1H-Purine-2,6-dione, 8-cyclopentyl-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 38048-32-7 HCAPLUS
CN Inosine, 6-S-[(4-nitrophenyl)methyl]-6-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 41094-88-6 HCAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(butylamino)-1-ethyl-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 51481-61-9 HCAPLUS
CN Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 53296-10-9 HCAPLUS
CN Adenosine, 2-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56715-13-0 HCAPLUS
CN Benzeneacetamide, 4-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 64710-63-0 HCAPLUS
CN 1H-Imidazole-4-ethanamine, 1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 75614-89-0 HCAPLUS
CN 1H-Imidazole-4-ethanamine, .alpha.-methyl-, dihydrochloride, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 HCl

RN 89805-39-0 HCAPLUS
CN Benzeneethanamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 93379-54-5 HCAPLUS
CN Benzeneacetamide, 4-[(2S)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 96850-13-4 HCAPLUS
CN 1H-Inden-1-amine, 3-(3,4-dichlorophenyl)-2,3-dihydro-N-methyl-, hydrochloride, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 100069-68-9 HCAPLUS
CN Silanol, cyclohexylphenyl[3-(1-piperidinyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 104809-20-3 HCAPLUS
CN Adenosine, 5'-[hydrogen [[hydroxy(phosphonooxy)phosphinyl]methyl]phosphonate], dilithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Li

RN 109028-10-6 HCAPLUS
CN Pyrrolo[1,2-a]quinoxaline, 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 109028-09-3
CMF C17 H17 F3 N4



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 123064-80-2 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 127299-93-8 HCAPLUS
CN Acetic acid, [4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]-, monosodium salt, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 147416-96-4 HCAPLUS
CN 10H-Thieno[3,4-b][1,5]benzodiazepin-10-one, 4,9-dihydro-3-methyl-4-[(4-methyl-1-piperazinyl)acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 148440-81-7 HCAPLUS
CN 1-Piperidinecarbothioamide, N-cyclohexyl-4-(1H-imidazol-4-yl)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 106243-16-7
CMF C15 H24 N4 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 149981-25-9 HCAPLUS
CN Benzenesulfonic acid, 4-[2,3,6,7-tetrahydro-3,7-dimethyl-2,6-dioxo-1-(2-propenyl)-1H-purin-8-yl]- (9CI) (CA INDEX NAME)



RN 153587-01-0 HCAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 175615-76-6 HCAPLUS
CN Silanol, cyclohexyl(4-fluorophenyl)[3-(1-piperidinyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192575-19-2 HCAPLUS
CN 1,3-Benzenedisulfonic acid, 4-[[4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]azo]-, tetrasodium salt (9CI) (CA INDEX NAME)



● 4 Na

RN 369647-58-5 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369647-59-6 HCAPLUS
CN 1,2-Ethanediol, 1-(4-hydroxy-3-methoxyphenyl)-, compd. with diethyldiazene (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 821-14-7
CMF C4 H10 N2

CM 2

CRN 534-82-7
CMF C9 H12 O4



RN 369647-60-9 HCAPLUS
CN Adenosine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with adenosine, triammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●3 NH_3

PAGE 1-B



L127 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:598462 HCAPLUS
DN 135:177709
TI Treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents
IN Balin, Brian J.; Abrams, J. Todd; Hudson, Alan P.; Whittum-Hudson, Judith A.
PA USA
SO U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K031-70
ICS A01N043-04
NCL 514029000
CC 9-10 (Biochemical Methods)
Section cross-reference(s): 1, 14, 15
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2001014670	A1	20010816	US 1999-227749	19990108 <--
PRAI US 1998-70855P	P	19980109 <--		

AB The invention relates to a method of treating **Alzheimer**'s disease in a mammal comprising administering to the mammal an anti-microbial agent having anti-Chlamydia pneumoniae activity. The invention also relates to a method of diagnosing **Alzheimer**'s disease in a mammal comprising measuring the serum anti-Chlamydia pneumoniae antibody titer in a patient suspected of having **Alzheimer**'s disease (AD). Immunohistochem. anal. of tissues from affected regions of AD brains and congruent regions from non-AD control brains was performed to identify specific area(s) and host cell types within which the bacterium resides. Immunohistochem. anal. confirmed the presence of C. pneumoniae in affected AD brain regions and localized the bacterium to non-**neuronal** cells. At least three cell types, astroglia, microglia, and pericytes, were shown to harbor C. pneumoniae in the AD brain.

ST **Alzheimer** disease treatment diagnosis Chlamydia pneumoniae; antibody Chlamydia pneumoniae blood **Alzheimer** diagnosis; antimicrobial Chlamydia **Alzheimer** disease treatment

IT rRNA
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(16 S, detection of microbial gene for; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Brain**
(Chlamydia pneumoniae localization in, of humans with **Alzheimer**'s disease; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Apolipoproteins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(E, genotype allele; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Test kits
(ELISA; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Glycoproteins, specific or class
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(MOMP (major outer membrane protein), detection of microbial gene for; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT PCR (polymerase chain reaction)
(RT-PCR (reverse transcription-PCR); treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Proteins, specific or class
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(Sezary T-cell activating factor (SAF), antibody to; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Cerebrospinal fluid
(anal. of; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Macrolides
Sulfonamides
Tetracyclines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibiotics; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Nervous system**

(central, anti-SAF antibody binding to tissue of; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Nervous system**
(central, infection; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Immunoassay
(enzyme-linked immunosorbent assay; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Brain**
(hippocampus, Chlamydia pneumoniae detection in, of humans with **Alzheimer**'s disease; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Immunoassay
(immunoelectron microscopy; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Immunoassay
(immunohistochem.; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Nucleic acid hybridization
(in situ, in situ-Pop; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Nucleic acid hybridization
(in situ; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Animal cell
Macrophage
Monocyte
Oligodendrocyte
(infected with Chlamydia pneumoniae, for drug screening; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Astrocyte**
(infection, with Chlamydia pneumoniae, for drug screening; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Nose
(intranasal sample of; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Drug delivery systems
(intrathecal; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Antibodies
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(labeled, to Sezary T-cell activating factor (SAF); treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Antibiotics
(macrolide; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Neuroglia**
(microglia, cells infected with Chlamydia pneumoniae, for drug screening; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Lipopolysaccharides
RL: ANT (Analyte); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(monoclonal antibody to; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Antibodies

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal, to Sezary T-cell activating factor (SAF); treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Drug delivery systems
(nasal; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Nerve**
(**neuron**, infected with Chlamydia pneumoniae, for drug screening; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Anti-inflammatory agents
(nonsteroidal; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT DNA
mRNA
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(of Chlamydia pneumoniae localization in brain of humans with **Alzheimer**'s disease; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Brain**
(olfactory bulb, Chlamydia pneumoniae detection in, of humans with **Alzheimer**'s disease; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Drug delivery systems
(oral; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Capillary vessel
(pericyte, Chlamydia pneumoniae detection in, of humans with **Alzheimer**'s disease; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Drug delivery systems
(systemic; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Brain**
(temporal cortex, Chlamydia pneumoniae detection in, of humans with **Alzheimer**'s disease; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT Antibodies
RL: ANT (Analyte); ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(to Chlamydia pneumoniae or to Sezary T-cell activating factor (SAF); treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **Alzheimer's disease**
Anti-inflammatory agents
Antibiotics
Antimicrobial agents
Blood analysis
Chlamydia pneumoniae
Diagnosis
Drug screening
Electron microscopy
Mammal (Mammalia)
PCR (polymerase chain reaction)
(treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT 329900-75-6, COX-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **50-33-9**, Phenylbutazone, biological studies 53-86-1, Indomethacin 60-54-8, Tetracycline 79-57-2, Oxytetracycline 91-22-5D, Quinoline, derivs.,antibiotic compds., biological studies 114-07-8, Erythromycin 564-25-0, Doxycycline 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 2751-09-9, Troleandomycin 5104-49-4, Flurbiprofen 10118-90-8, Minocycline 13710-19-5, Tolfenamic acid 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 31793-07-4, Pirprofen 33005-95-7, Tiaprofenic acid 36322-90-4, Piroxicam 38194-50-2, Sulindac 62013-04-1, Dirithromycin 81103-11-9, Clarithromycin 82419-36-1, Ofloxacin 83905-01-5, Azithromycin 85721-33-1, Ciprofloxacin
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

IT **50-33-9**, Phenylbutazone, biological studies
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment and diagnosis of **Alzheimer**'s disease with anti-Chlamydia pneumoniae agents)

RN 50-33-9 HCAPLUS

CN 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



L127 ANSWER 13 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:594375 HCAPLUS

DN 135:142289

TI Timed **pulsatile** drug delivery systems containing polymers

IN Percel, Phillip; Vishnupad, Krishna S.; Venkatesh, Gopi M.

PA Eurand America, Incorporated, USA

SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW

DT **Patent**

LA English

IC ICM A61K009-50
ICS A61K031-18

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1123700	A1	20010816	EP 2001-103129	20010209 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2001046964	A1	20011129	US 2001-778645	20010207 <--
	WO 2001058433	A1	20010816	WO 2001-US4012	20010208 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-181867P P 20000211 <--
AB A pharmaceutical dosage form such as a capsule capable of delivering therapeutic agents into the body in a time-controlled or position-controlled pulsatile release fashion, is composed of a multitude of multicoated particulates (beads, pellets, granules, etc.,) made of 1 or more populations of beads. Each of these beads except an immediate release bead has at least 2 coated membrane barriers. One of the membrane barriers is composed of an enteric polymer while the second membrane barrier is composed of a mixt. of water insol. polymer and an enteric polymer. The compn. and the thickness of the polymeric membrane barriers det. the lag time and duration of drug release from each of the bead populations. Optionally, an org. acid contg. intermediate membrane may be applied for further modifying the lag time and/or the duration of drug release. The pulsatile delivery may comprise one or more pulses to provide a plasma concn.-time profile for a therapeutic agent, predicted based on both its pharmacokinetic and pharmacodynamic considerations and in vitro/in vivo correlations. Thus, a formulation contained in the core, sotalol-HCl 8.80, sugar spheres 33.91, and povidone 0.43, in the seal coating Opadry Clear YS-1-7006 0.88, in the inner coating methacrylic acid copolymer 8.46, talc 1.69, and acetyl tri-Bu citrate 0.85, in the outer coating methacrylic acid copolymer 20.47, acetyl tri-Bu citrate 2.02, Et cellulose aq. dispersion 18.14, di-Bu sebacate 4.36% by wt., and water traces.
ST timed pulsatile drug delivery polymer
IT Monoglycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acetates; timed pulsatile drug delivery systems contg. polymers)
IT Drug delivery systems
(granules, sustained release; timed pulsatile drug delivery systems contg. polymers)
IT Drug delivery systems
(pellets, sustained-release; timed pulsatile drug delivery systems contg. polymers)
IT Analgesics
Anesthetics
Anti-infective agents
Anticonvulsants
Antidiabetic agents
Antiparkinsonian agents
Antirheumatic agents
Antitumor agents
Cardiovascular agents
Digestive tract
Dissolution rate
Dopamine agonists
Extrusion, nonbiological
Granulation
Milling (size reduction)
Nervous system stimulants
Plasticizers
Psychotropics
Spheronization
Urinary tract
(timed pulsatile drug delivery systems contg. polymers)
IT Castor oil
Shellac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(timed pulsatile drug delivery systems contg. polymers)
IT 77-90-7, Acetyl tributyl citrate 77-93-0, Triethyl citrate 77-94-1,

Tributyl citrate 84-66-2, Diethyl phthalate 102-76-1, Triacetin 109-43-3, Dibutyl sebacate 113-45-1, Methylphenidate 114-07-8, Erythromycin 152-11-4, Verapamil hydrochloride 554-13-2, Lithium carbonate 959-24-0, Sotalol hydrochloride 9003-39-8, PVP 9004-34-6D, Cellulose, esters, biological studies 9004-57-3, Ethyl cellulose **15307-79-6**, Diclofenac sodium 21829-25-4, Nifedipine 25086-15-1, Methacrylic acid-methyl methacrylate copolymer 26787-78-0, Amoxicillin 28860-95-9, Carbidopa 31677-93-7, Bupropion hydrochloride 51022-70-9, Albuterol sulfate 53237-50-6 53994-73-3, Cefaclor 56392-17-7, Metoprolol tartrate 72509-76-3, Felodipine 73590-58-6, Omeprazole 79794-75-5, Loratidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(timed pulsatile drug delivery systems contg. polymers)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Abramowitz, R; US 5536507 A 1996 HCAPLUS
(2) Brunetti, G; US 5900252 A 1999 HCAPLUS
(3) Chih-Ming, C; US 5472708 A 1995 HCAPLUS
(4) Chih-Ming, C; US 5837379 A 1998 HCAPLUS
(5) Kinaform Technology Inc; EP 0391518 A 1990 HCAPLUS

IT **15307-79-6**, Diclofenac sodium
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(timed pulsatile drug delivery systems contg. polymers)

RN 15307-79-6 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L127 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:725465 HCAPLUS

DN 133:276367

TI Method for the treatment of **neurological** or **neuropsychiatric** disorders with melatonin antagonists

IN Willis, Gregory Lynn

PA Clarence Pty Ltd, Australia

SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2

DT **Patent**

LA English

IC ICM A61K031-4045
ICS A61K031-165; A61K031-17; A61K031-445; A61K031-4965; A61K031-5375; A61K031-54; A61P025-14; A61P025-16; A61P025-18; A61P025-22; A61P025-24; A61P025-28

CC 1-11 (Pharmacology)
Section cross-reference(s): 14, 28

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059504	A1	20001012	WO 2000-AU275	20000331 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6310085	B1	20011030	US 1999-285859	19990402	<--
BR 2000009524	A	20020219	BR 2000-9524	20000331	<--
EP 1189613	A1	20020327	EP 2000-912271	20000331	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002541105	T2	20021203	JP 2000-609068	20000331	<--
EE 200100511	A	20021216	EE 2001-511	20000331	<--
NO 2001004674	A	20010926	NO 2001-4674	20010926	<--
PRAI US 1999-285859	A	19990402	<--		
WO 1997-AU661	A2	19971003	<--		
WO 2000-AU275	W	20000331	<--		

OS MARPAT 133:276367

GI



I



II

AB A method for the treatment and/or prophylaxis of a **neurol**. or **neuropsychiatric** disorder assocd. with altered dopamine function comprises administering melatonin antagonists I (X = NO2, N3; Y = H, I) or II [R = H, OR4; R1 = H, COOR5; R2 = H, (substituted) alkyl; R3 = CO(CH2)nR6, C(=X)NH(CH2)nR7; R4 = H, (un)substituted alkyl, cycloalkyl, etc.; R5 = H, (un)substituted alkyl; R6 = H, (un)substituted alkyl, alkene, etc.; R7 = H, (un)substituted alkyl, etc.; n = 0-3; X = O, S] to a patient in need thereof. I (X = NO2; Y = H) (ML-23) prevented the development of severe motor impairment typically exhibited by **neurotoxin** 6-hydroxydopamine-treated rats. All rats treated with ML-23 recovered and were capable of regulating their body wt.

ST **nervous** system **neuropsychiatric** disorder treatment melatonin antagonist; movement disorder treatment ML 23; dopamine mental disorder treatment melatonin antagonist

IT **Nervous system**
(**Huntington's chorea**; **neurol**. or **neuropsychiatric** disorders treatment with melatonin antagonists)

IT **Mental disorder**
(Pick's disease; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Mental disorder**
(Punch drunk syndrome; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT Stress, animal
(acute; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Mental disorder**
(agoraphobia; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT Appetite
(anorexia **nervosa**; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Mental disorder**
(depression, anxiety disorders due to; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Nervous system**
(disease, malignant syndrome; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Nervous system**
(disease, multiple systems atrophy; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Nervous system**
(disease; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Nervous system**
(dystonia, acute; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Nerve, disease**
(**ischemia**, trans-; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT Behavior
(motor, melatonin release in relation to; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Alzheimer's disease**
Anorexia
Anxiety
Anxiolytics
Cachexia
Drug delivery systems
Mental disorder
Movement disorders
Multiple sclerosis
Parkinson's disease
Phototherapy
Schizophrenia
Veterinary medicine
Wernicke-Korsakoff syndrome
(**neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Mental disorder**
(obsession-compulsion; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT Anxiety
(panic disorder; **neurol.** or **neuropsychiatric**

disorders treatment with melatonin antagonists)
IT **Mental disorder**
(post-traumatic stress disorder; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT Paralysis
(pseudobulbar; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Brain, disease**
(**stroke; neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **Nervous system**
(tardive dyskinesia; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **29122-68-7**, Atenolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**Parkinson's** disease treatment with bright light therapy and; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT **51-61-6**, Dopamine, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(altered; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT 73-31-4, Melatonin
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT 1199-18-4, 6-Hydroxydopamine
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT 152302-33-5, S-20928
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
IT 115007-18-6, ML-23
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Adir Et Compagnie; WO 9958495 1999 HCAPLUS
(2) Andrieux; US 5318994 1994 HCAPLUS
(3) Lesieur; US 5385944 1995 HCAPLUS
(4) Tenn; Brain Research 1997, V756, P293 HCAPLUS
(5) Willis; WO 9815267 1998 HCAPLUS
(6) Ying; European Journal of Pharmacology 1996, V296, P33 HCAPLUS
(7) Yous; US 5420158 1995 HCAPLUS
(8) Yous; US 5616614 1997 HCAPLUS
(9) Zisapel; US 4880826 1989 HCAPLUS
IT **29122-68-7**, Atenolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**Parkinson's** disease treatment with bright light therapy and; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
RN 29122-68-7 HCAPLUS

CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



IT **51-61-6**, Dopamine, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (altered; **neurol.** or **neuropsychiatric** disorders treatment with melatonin antagonists)
RN 51-61-6 HCAPLUS
CN 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) (CA INDEX NAME)



L127 ANSWER 15 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:290832 HCAPLUS
DN 132:318003
TI Method and composition for modulating **amyloidosis**
IN Reiner, Peter B.; Lam, Fred Chiu-lai
PA The University of British Columbia, Can.
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-00
CC 1-1 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000024390	A1	20000504	WO 1999-US23885	19991014	<--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	US 2002037843	A1	20020328	US 1998-177413	19981023	<--
	US 6514686	B2	20030204			
	EP 1123090	A1	20010816	EP 1999-954894	19991014	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	JP 2002528411	T2	20020903	JP 2000-578000	19991014	<--
PRAI	US 1998-177413	A2	19981023	<--		

US 1997-847616 B2 19970428 <--
US 1998-67523 B2 19980428 <--
WO 1999-US23885 W 19991014 <--

AB Methods for modulating **amyloid** deposition in a subject are described. An effective amt. of at least one ATP-binding cassette (ABC) transporter blocker is administered to a subject, such that modulation of **amyloid** deposition occurs. Methods also include administering an effective amt. of at least one ABC transporter blocker, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state assocd. with **amyloidosis** is treated. Packaged pharmaceutical compns. for treating **amyloidosis** are described. The package includes a container for holding an effective amt. of a pharmaceutical compn. and instructions for using the pharmaceutical compn. for treatment of **amyloidosis**. The pharmaceutical compn. includes at least one ABC blocker for modulating **amyloid** deposition in a subject. Methods for identifying agents which modulate **amyloid** deposition in a subject are also described. An effective amt. of at least one ATP binding cassette (ABC) transporter blocker is administered to an organism, such that modulation of **amyloid** deposition occurs.

ST **amyloid** deposition modulation ATP binding cassette transporter blocker

IT **Brain**
(ABC transporter blockade in; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT EST (expressed sequence tag)
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(ABC transporter blocker-encoding; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ABC1, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ABC2, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ABC3, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ABC7, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ABC8, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **Alzheimer's disease**
Amyloidosis
Anti-Alzheimer's agents
Bilayer membranes
Cell membrane
Drug screening
Liposomes
Membrane, biological

Multidrug resistance
(ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ATP binding cassette (ABC) transporter, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MDR1, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MRP4, inhibitors; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MRP5, inhibitors; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT P-glycoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **Amyloid precursor proteins**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cleavage of; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT **Amyloid**
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(deposition of; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Biological transport
(efflux, pump; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Labels
(for drug packaging; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Packaging materials
(for drugs; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Head
(injury; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mdr3, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Blood vessel
(microvessel, of brain, ABC transporter blockade in; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Protein degradation
(of **amyloid** precursor protein; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)

IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phospholipid-transporting, blockers; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)
IT **Brain, disease**
(**stroke**; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)
IT **Amyloid**
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(.beta.-; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)
IT 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 51-55-8, Atropine, biological studies 52-53-9, Verapamil 54-05-7, Chloroquine **57-47-6**, Physostigmine 61-54-1, Tryptamine 65-61-2, Acridine orange 83-89-6, Quinacrine 90-34-6, Primaquine 117-89-5, Trifluoperazine 130-95-0, Quinine 146-48-5, Yohimbine 260-94-6, Acridine 483-10-3, Corynanthine 485-71-2, Cinchonidine 525-66-6, Propranolol 10540-29-1, Tamoxifen 59865-13-3, Cyclosporin 59865-15-5 64657-18-7, 1,9-Dideoxyforskolin 66575-29-9, Forskolin 84371-65-3, RU-486 92302-55-1 104987-11-3, FK-506 119666-09-0, AHC-52 121584-18-7, PSC-833 129716-45-6, MS-073 140945-01-3, S9788 143664-11-3, GF120918 158681-49-3, MS-209 159997-94-1, VX-710 190454-58-1, VX-853
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)
IT 123955-65-7, RU 49953
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RU 49953; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)
IT 180422-22-4, XR 9051
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(XR 9051; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)
IT 56-65-5, Atp, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cassette binding; ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Lam Fred Chiu Lai; WO 9848784 A 1998 HCAPLUS
IT **57-47-6**, Physostigmine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(ATP binding cassette (ABC) transporter blocker for modulating **amyloidosis**)
RN 57-47-6 HCAPLUS
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L127 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:227858 HCAPLUS
DN 132:260666
TI Identifying agents that alter mitochondrial permeability transition pores and **cell death** for diagnostic and therapeutic use
IN Dykens, James A.; Miller, Scott W.; Ghosh, Soumitra S.; Davis, Robert E.
PA Mitokor, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM G01N033-50
ICS G01N033-68; A61K031-00; C07C279-26
CC 1-1 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000019200	A1	20000406	WO 1999-US22261	19990924 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003044776	A1	20030306	US 1998-161172	19980925 <--
	CA 2345066	AA	20000406	CA 1999-2345066	19990924 <--
	AU 9961628	A1	20000417	AU 1999-61628	19990924 <--
	EP 1116027	A1	20010718	EP 1999-948458	19990924 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002525630	T2	20020813	JP 2000-572655	19990924 <--
PRAI	US 1998-161172	A	19980925 <--		
	WO 1999-US22261	W	19990924 <--		

AB Methods are provided for identifying agents that affect mitochondrial functions and cell death. Such agents are useful for treating diseases assocd. with mitochondrial dysfunction and in methods of identifying a risk or presence of such diseases. In particular, the invention relates to the loss of mitochondrial membrane potential (.DELTA..PSI.m) during mitochondrial permeability transition (MPT) and further provides a measurable rate loss function, changes in which are useful e.g. for detecting agents that affect one or more mitochondrial functions, for

detecting mitochondrial diseases, and for studying mol. components of mitochondria that regulate MPT.

ST mitochondria permeability transition pore therapeutic identification; diagnosis mitochondrial disease permeability transition pore; cell death mitochondrial permeability therapeutic identification; membrane potential mitochondria diagnostic therapeutic identification

IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ADP/ATP carrier; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Cyclophilins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(D; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Apolipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E, genotype; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT **Nervous system**
(**Huntington's chorea**; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT **Brain, disease**
(**MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes**); identification of agents that alter mitochondrial permeability transition pores and cell **death** for diagnostic and therapeutic use)

IT Muscle, disease
(MERRF (myoclonic epilepsy assocd. with ragged-red muscle fibers); identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Animal cell line
(SH-SY5Y, cybrid cell produced with; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Annexins
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(V, FITC conjugates; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Anion channel
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(VDAC (voltage-dependent anion-selective channel); identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT **Neurotransmitters**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(amino acid; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT **Diabetes mellitus**
(and mitochondrial diabetes and deafness; identification of agents that

alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(bcl-2, Bcl-2 gene family-encoded polypeptide; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Membrane potential
(biol.; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(calcium-transporting, mitochondrial calcium uniporter; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Platelet (blood)
(cybrid cell produced with; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Animal cell
(cybrid cell; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Muscle, disease
(degeneration; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Mitochondria
(diseases; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT **Nervous system**
(dystonia; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Pathogen
(eukaryotic; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Indicators
(for inner mitochondrial membrane potential; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Eye, disease
(hereditary optic atrophy; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Cell proliferation
(hyperproliferative disease; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Affinity labeling
Alzheimer's disease
Anti-Alzheimer's agents
Antidiabetic agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Apoptosis
Brain, disease
Cell death

Cytotoxic agents
Diagnosis
Drug delivery systems
Drug screening
Electron transport system, biological
Fluorometry
Genotypes
Insect (Insecta)
Ionophores
Lepidoptera
Mitochondria
Necrosis
Neoplasm
Nucleic acid library
Parkinson's disease
Plant (Embryophyta)
Psoriasis
Schizophrenia
(identification of agents that alter mitochondrial permeability transition pores and cell **death** for diagnostic and therapeutic use)

IT DNA
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Mitochondria
Mitochondria
(inner membrane; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Membrane, biological
Membrane, biological
(inner mitochondrial; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Biological transport
(intracellular, phosphatidylserine; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Acidosis
(lactic; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Time-of-flight mass spectrometry
Time-of-flight mass spectrometry
(laser-induced photodesorption; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Deafness
(mitochondrial diabetes and deafness; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Amino acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**neurotransmitter**; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Parasite
(of human; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Eukaryote (Eukaryotae)

(pathogen; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Benzodiazepine receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peripheral; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Biological transport
(permeation; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Laser ionization mass spectrometry
Laser ionization mass spectrometry
(photodesorption, matrix-assisted; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Laser desorption mass spectrometry
Laser desorption mass spectrometry
(photoionization, matrix-assisted; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Proliferation inhibition
(proliferation inhibitors; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Laser desorption mass spectrometry
Laser desorption mass spectrometry
(time-of-flight; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Antibodies
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(to cytochrome c; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT Phosphatidylserines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(translocation; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT 145037-81-6, Rhod 2
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(Rhod 2; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT 9007-43-6, Cytochrome c, biological studies 122191-40-6, Caspase 1 169592-56-7, Caspase 3 186322-81-6, Caspase
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT 51-83-2, Carbachol 56-86-0, L-Glutamic acid, biological studies 6384-92-5, N-Methyl-D-aspartic acid 11076-19-0, Bongkrekic acid 11103-72-3, Ruthenium red 17754-44-8, Atractyloside 56092-81-0, Ionomycin 67526-95-8, Thapsigargin 79217-60-0, Cyclosporin 169332-61-0 182374-54-5D, derivs. 201608-13-1 217174-04-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT **102-02-3**, 1-Phenylbiguanide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT 7440-70-2, Calcium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT 2156-29-8 3520-43-2, JC-1 18198-39-5, Tetraphenylphosphonium 27072-45-3D, Fluorescein isothiocyanate, annexin V conjugates 30827-04-4, Rhodamine B hexyl ester 53213-82-4, DiOC6(3) 62669-70-9, Rhodamine 123 115532-49-5 137993-41-0, Rhodamine 800 139626-15-6, Tetramethylrhodamine ethyl ester
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT 9001-15-4, Creatine kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mitochondrial intermembrane; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

IT 9001-51-8, Hexokinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mitochondrial-assocd.; identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Beal, M; Biochimica et Biophysica Acta 1998, V1366(1-2), P211 HCAPLUS
(2) Diamond, J; GB 1410925 A 1975 HCAPLUS
(3) Friberg, H; Journal of Neuroscience 1998, V18(14), P5151 HCAPLUS
(4) Hirsch, T; Cell Biology and Toxicology 1998, V4(2), P141

IT **102-02-3**, 1-Phenylbiguanide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(identification of agents that alter mitochondrial permeability transition pores and cell death for diagnostic and therapeutic use)

RN 102-02-3 HCAPLUS
CN Imidodicarbonimidic diamide, N-phenyl- (9CI) (CA INDEX NAME)



L127 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:169319 HCAPLUS
DN 132:212709
TI Pharmaceutical composition containing tarcine for the treatment of

neurological diseases

IN Guittard, George V.; Childers, Jerry D.; Wong, Patrick S. L.; Gumucio, Fernando E.; Kidney, David J.
PA Alza Corporation, USA

SO U.S., 16 pp., Cont.-in-part of U.S. 5,698,224.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K009-00
ICS A61K031-13; A61K031-135
NCL 424457000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6036973	A	20000314	US 1997-892995	19970715 <--
US 5698224	A	19971216	US 1994-266045	19940627 <--
CA 2187332	AA	19960104	CA 1995-2187332	19950614 <--
PRAI US 1994-266045		19940627 <--		

AB A dosage form is disclosed for administering 10 ng to 1200 mg tacrine to a patient in need of tacrine therapy. A core comprising 86.15 mg of tacrine hydrochloride, 86.15 mg of mannitol, 7.25 mg of poly(vinylpyrrolidone) and 1.81 mg of magnesium stearate was prepd. A semipermeable wall was coated around the individual, sep. cores comprising 80 % cellulose acetate having a 39.8% acetyl content and 20 % poly(vinylpyrrolidone). An exit passageway was drilled through the semipermeable wall connecting the tacrine with the exterior of each dosage form. The exit port had a diam. of 30 mils (0.76 mm) and each dosage form dispensed tacrine for 24 h.

ST pharmaceutical tablet tarcine **neurol** disease
IT **Nervous system**
(disease; pharmaceutical compn. contg. tarcine for treatment of **neurol**. diseases)
IT **Alzheimer's disease**
(pharmaceutical compn. contg. tarcine for treatment of **neurol**. diseases)
IT Estrogens
Phosphatidylserines
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. contg. tarcine for treatment of **neurol**. diseases)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. contg. tarcine for treatment of **neurol**. diseases)
IT Drug delivery systems
(sustained-release; pharmaceutical compn. contg. tarcine for treatment of **neurol**. diseases)
IT **57-47-6**, Physostigmine 59-02-9, .alpha.-Tocopherol 321-64-2, Tacrine 485-35-8, Cytisine **504-24-5**, Fampridine 1684-40-8, Tacrine hydrochloride 14611-51-9, Selegiline 26445-05-6, Aminopyridine 55242-55-2, Propentofylline 66085-59-4, Nimodipine 68497-62-1, Pramiracetam 72432-10-1, ANiracetam 90293-01-9, Bifemelane 105431-72-9, Linopirdine 120014-06-4, Donepezil 124027-47-0, 1-Hydroxy-tacrine 174528-42-8, Tacrine hydrobromide 174528-43-9, Tacrine sulfate 174528-44-0, Tacrine phosphate 174528-45-1, Tacrine lactate 174528-46-2, Tacrine citrate 174528-47-3, Tacrine malate 174528-48-4, Tacrine maleate 174528-49-5, Tacrine fumarate 174528-50-8 174528-51-9 174528-52-0, Tacrine aspartate 174528-53-1, Tacrine salicylate 174528-54-2, Tacrine edisylate 174528-55-3, Tacrine laurate 174528-56-4, Tacrine palmitate 174528-57-5, Tacrine nitrate

174528-58-6, Tacrine borate 174528-59-7, Tacrine acetate 174528-60-0, Tacrine oleate 174672-18-5, Tacrine tartrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical compn. contg. tarcine for treatment of **neurol** . diseases)

IT 50-70-4, Sorbitol, biological studies 9003-39-8, Poly(vinylpyrrolidone) 9004-32-4, Sodium CM-cellulose 9004-35-7, Cellulose acetate 9004-64-2, Hydroxypropylcellulose 9004-65-3, Hydroxypropylmethylcellulose 25322-68-3, Polyethylene glycol;
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. contg. tarcine for treatment of **neurol** . diseases)

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; WO 9215285 1992 HCAPLUS
(2) Anon; WO 9324154 1993 HCAPLUS
(3) Anon; EP 0595365 A1 1994 HCAPLUS
(4) Anon; WO 9503052 1995 HCAPLUS
(5) Cortese; US 4327725 1982
(6) Guittard; US 5698224 1997 HCAPLUS
(7) Higuchi; US 5916925 1999 HCAPLUS
(8) Saunders; US 4063064 1977
(9) Stephen; US 4857330 1989
(10) Summers; US 4816456 1989 HCAPLUS
(11) Theeuwes; US 3845770 1974 HCAPLUS
(12) Theeuwes; US 3916899 1975 HCAPLUS
(13) Theeuwes; US 4077407 1978 HCAPLUS
(14) Theeuwes; US 4088864 1978
(15) Wong; US 4612008 1986
(16) Wong; US 4765989 1988 HCAPLUS
(17) Wong; US 4783337 1988 HCAPLUS
(18) Wurster; US 2799241 1957
(19) Wurster, D; J Am Phar Assoc, Sci Ed 1959, V48, P451 MEDLINE
(20) Wurster, D; J Am Phar Assoc, Sci Ed 1960, V49, P82 MEDLINE

IT **57-47-6**, Physostigmine **504-24-5**, Fampridine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical compn. contg. tarcine for treatment of **neurol** . diseases)

RN 57-47-6 HCAPLUS

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 504-24-5 HCAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)



L127 ANSWER 18 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:672562 HCAPLUS
DN 131:281590
TI Methods for treating **neuropsychiatric** disorders
IN Tsai, Guochuan; Coyle, Joseph
PA The General Hospital Corporation, USA
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-00
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952519	A2	19991021	WO 1999-US8056	19990414 <--
	WO 9952519	A3	19991202		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2328197	AA	19991021	CA 1999-2328197	19990414 <--
	AU 9935571	A1	19991101	AU 1999-35571	19990414 <--
	EP 1073432	A2	20010207	EP 1999-917453	19990414 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6228875	B1	20010508	US 1999-291296	19990414 <--
	JP 2002511409	T2	20020416	JP 2000-543129	19990414 <--
	US 2002035145	A1	20020321	US 2001-834351	20010413 <--
	US 6420351	B1	20020716		
	US 2002193429	A1	20021219	US 2002-196686	20020715 <--
PRAI	US 1998-81645P	P	19980414 <--		
	US 1999-291296	A1	19990414 <--		
	WO 1999-US8056	W	19990414 <--		
	US 2001-834351	A1	20010413		

AB The invention provides methods for treating **neuropsychiatric** disorders such as schizophrenia, **Alzheimer**'s Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder. The methods entail administering to a patient with a **neuropsychiatric** disorder a pharmaceutical compn. contg. (i) a therapeutically effective amt. of D-alanine (or a modified form), provided that the compn. is substantially free of D-cycloserine, and/or (ii) D-serine (or a modified form), and/or (iii) 105 to 500 mg of D-cycloserine (or a modified form), and/or (iv)

N-methylglycine (or a modified form). Using double-blind conditions, patients were randomly assigned to receive placebo (fruit juice), D-serine 30, D-alanine 60-100, or N-methylglycine 30 mg/kg/day once a day by mouth for 6 wk. Treatment with D-serine, D-alanine, or N-methylglycine improved the schizophrenic symptoms and **cognitive** deficit of the patients. Specifically, treatment with D-serine resulted in a 21% redn. of the neg. symptoms (on the SANS scale), and it resulted in a 17% redn. of the pos. symptoms. Treatment with D-alanine resulted in an 11% redn. of the neg. symptoms and a 12% redn. of the pos. symptoms. Reatment with N-methylglycine resulted in a 20% redn. of the neg. symptoms and a 15% redn. of the pos. symptoms. These redns. in the neg. and pos. symptoms represented clin. significant improvement.

ST **neuropsychiatric** disorder treatment serine alanine cycloserine; methylglycine **neuropsychiatric** disorder treatment; antidepressant serine alanine cycloserine

IT **Mental disorder**
(attention deficit disorder; methods for treating **neuropsychiatric** disorders)

IT **Mental disorder**
(autism; methods for treating **neuropsychiatric** disorders)

IT **Anti-Alzheimer's agents**
Antidepressants
Antipsychotics
Cognition enhancers
Mental disorder
Psychostimulants
Schizophrenia
(methods for treating **neuropsychiatric** disorders)

IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 51-64-9, Dextroamphetamine 51-71-8, Phenelzine 52-86-8, Haloperidol 58-39-9, Perphenazine 68-41-7, D-CycloSerine 68-41-7D, D-CycloSerine, derivs. 68-41-7D, D-CycloSerine, salts and complexes 69-23-8, Fluphenazine 72-69-5, Nortriptyline 107-43-7, N,N,N-TriMethylglycine 107-97-1, N-Methylglycine 107-97-1D, N-Methylglycine, derivs. 113-45-1, Methylphenidate 113-59-7, Chlorprothixene 117-89-5, Trifluoperazine 155-09-9, TRanylcypromine 303-49-1, Clomipramine 312-84-5, D-Serine 312-84-5D, D-Serine, derivs. 321-64-2, Tacrine 338-69-2, D-Alanine 338-69-2D, D-Alanine, derivs. 438-60-8, Protriptyline 537-46-2, Methamphetamine 548-73-2, Droperidol 653-03-2, Butaperazine 1118-68-9, N,N,-DiMethylglycine 1668-19-5, Doxepin 1977-10-2, Loxapine 2062-78-4, Pimozide 2152-34-3, Pemoline 2622-30-2, Carphenazine 2746-81-8, Fluphenazine enanthate 2751-68-0, Acetophenazine 3313-26-6, Thiothixene 3819-00-9, Piperacetazine 5002-47-1, Fluphenazine decanoate 5588-33-0, Mesoridazine 5786-21-0, Clozapine 7416-34-4, Molindone 10262-69-8, Maprotiline 14028-44-5, Amoxapine **15676-16-1**, Sulpiride 15975-28-7 19794-93-5, Trazodone 32342-58-8, Sodium D-Alanine 34911-55-2, Bupropion 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 61869-08-7 74050-97-8, Haloperidol decanoate 79617-96-2, Sertraline 80125-14-0, Remoxipride 83366-66-9, Nefazodone 85650-52-8, Mirtazapine 106266-06-2, Risperidone 109026-02-0, D-Alanine, monopotassium salt 111974-69-7, Quetiapine 120014-06-4, Donepezil 132539-06-1, Olanzapine 146939-27-7, Ziprasidone 152005-29-3 246855-94-7 246855-95-8 246855-97-0 246855-99-2 246875-51-4 246875-52-5 246875-53-6 246875-54-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(methods for treating **neuropsychiatric** disorders)

IT 56-40-6, Glycine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(uptake inhibitors; methods for treating **neuropsychiatric**

disorders)
IT **15676-16-1**, Sulpiride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(methods for treating **neuropsychiatric** disorders)
RN 15676-16-1 HCAPLUS
CN Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



L127 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN **1999:344848** HCAPLUS
DN **131:714**
TI Therapeutic uses of triazolo-pyridazine derivatives
IN Castro Pineiro, Jose Luis; Hefti, Franz Fridolin; Hill, Raymond George; McKernan, Ruth; Tattersall, Frederick David; Whiting, Paul John
PA Merck Sharp & Dohme Limited, UK
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-50
ICS A61K031-00; A61K045-06
CC 1-11 (**Pharmacology**)
Section cross-reference(s): **63**
FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	WO 9925353	A1	19990527		WO 1998-GB3328	19981106	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
	AU 9910415	A1	19990607		AU 1999-10415	19981106	<--
	US 6174886	B1	20010116		US 1998-191304	19981112	<--
	US 6107296	A	20000822		US 1998-206416	19981207	<--
	US 6110915	A	20000829		US 1998-208288	19981208	<--
	US 6046196	A	20000404		US 1998-208291	19981209	<--
	US 6063783	A	20000516		US 1998-209071	19981210	<--
PRAI	GB 1997-23999	A	19971113	<--			
	GB 1997-26699	A	19971218	<--			
	GB 1997-26700	A	19971218	<--			
	GB 1997-26701	A	19971218	<--			
	GB 1997-26702	A	19971218	<--			
	GB 1998-1581	A	19980123	<--			

WO 1998-GB3328 W 19981106 <--
OS MARPAT 131:714
AB A class of substituted or 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivs., possessing an optionally substituted cycloalkyl, Ph or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABAA receptors, in particular having high affinity for the .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders including schizophrenia; **neurodegeneration** arising from cerebral ischemia; pain; emesis; and muscle spasm or spasticity, e.g. in paraplegic patients.
ST triazolopyridazine deriv GABAA ligand therapeutic; antipsychotic schizophrenia analgesic antiemetic triazolopyridazine deriv; **neurodegeneration** cerebral ischemia triazolopyridazine deriv; muscle spasm spasticity triazolopyridazine deriv
IT 5-HT antagonists
(5-HT3; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
IT GABA agonists
(GABAA; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
IT GABA receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(GABAA; triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)
IT Tachykinin receptors
(NK1 antagonists; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NMDA-binding, strychnine-insensitive glycine modulatory site of NMDA receptor; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
IT Opioids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analgesic; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
IT **Nerve**
(**degeneration**, from cerebral **ischemia**; triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)
IT **Neurotransmission**
(glutamatergic, modulators; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
IT **Brain, disease**
(**ischemia, neurodegeneration** from; triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)
IT Cytoprotective agents
(**neuroprotectants**; triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)
IT Anti-inflammatory agents
(nonsteroidal; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
IT Drug delivery systems
(prodrugs; triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)
IT Muscle relaxants
(spasmolytics; triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)
IT Cholinergic antagonists
Dopamine antagonists

(triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)

IT Analgesics
Antiemetics
Antipsychotics
Drug delivery systems
Muscle relaxants
(triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)

IT 39391-18-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2, inhibitors; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)

IT 12794-10-4D, Benzodiazepine, derivs.
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GABAA receptor benzodiazepine binding site; triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)

IT 56-40-6, Glycine, biological studies 57-24-9, Strychnine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(strychnine-insensitive glycine modulatory site of NMDA receptor; triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)

IT 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 52-86-8, Haloperidol 58-39-9, Perphenazine 69-23-8, Fluphenazine 113-59-7, Chlorprothixene 117-89-5, Trifluoperazine 1134-47-0, Baclofen 1977-10-2, Loxapine 2062-78-4, Pimozide 2751-68-0, Acetophenazine 3313-26-6, Thiothixene 5588-33-0, Mesoridazine 5786-21-0, Clozapine 7416-34-4, Molindone **15676-16-1**, Sulpiride 71125-38-7, Meloxicam 106266-06-2, Risperidone 127625-29-0, Fananserin 131986-45-3, Xanomeline 132539-06-1, Olanzapine 146939-27-7, Ziprasidone 162011-90-7, Rofecoxib 169590-42-5, Celecoxib
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)

IT 202929-19-9 202929-20-2 202929-21-3 202929-22-4 202929-23-5
202929-26-8 202929-27-9 202929-28-0 202929-29-1 202929-31-5
202929-32-6 202929-33-7 202929-34-8 202929-35-9 202929-36-0
202929-37-1 202929-38-2 202929-39-3 202929-40-6 202929-41-7
202929-42-8 202929-43-9 202929-44-0 202929-45-1 202929-47-3
202929-48-4 202929-49-5 202929-50-8 202929-51-9 202929-52-0
202929-53-1 202929-54-2 202929-55-3 202929-56-4 202929-57-5
202929-58-6 202929-59-7 202929-60-0 202929-61-1 202929-62-2
202929-63-3 202929-64-4 202929-66-6 202929-67-7 202929-68-8
202929-69-9 202929-70-2 202929-71-3 202929-72-4 202929-75-7
202929-77-9 202929-79-1 202929-80-4 202929-81-5 202929-82-6
202929-83-7 202929-84-8 202929-85-9 202929-86-0 202929-87-1
202929-88-2 202929-89-3 202929-90-6 202929-91-7 202929-92-8
202929-93-9 202929-94-0 202929-95-1 202929-96-2 202929-97-3
202929-98-4 202929-99-5 202930-00-5 202930-01-6 202930-02-7
202930-03-8 202930-04-9 202930-05-0 202930-06-1 202930-07-2
202930-08-3 202930-09-4 202930-10-7 202930-11-8 202930-12-9
202930-13-0 202930-14-1 202930-15-2 202930-16-3 202930-17-4
202930-18-5 202930-19-6 202930-20-9 202930-21-0 202930-22-1
202930-23-2 202930-24-3 202930-25-4 202930-26-5 202930-27-6
202930-28-7 202930-29-8 202930-30-1 202930-31-2 202930-32-3
202930-33-4 202930-34-5 202930-35-6 202930-36-7 202930-38-9
202930-39-0 202930-40-3 202930-41-4 202930-42-5 202930-43-6
202930-44-7 202930-45-8 202930-46-9 202930-47-0 202930-48-1
202930-49-2 202930-50-5 202930-51-6 202930-52-7 202930-55-0
202930-57-2 202930-59-4 202930-60-7 202930-61-8 202930-62-9
202930-63-0 202930-64-1 202930-65-2 202930-66-3 202930-68-5

202930-71-0 202930-76-5 202930-80-1 202930-83-4 202930-86-7
202930-88-9 202930-90-3 202930-92-5 202930-94-7 202930-96-9
202930-98-1 202930-99-2 202931-01-9 202931-03-1 202931-05-3
202931-07-5 202931-08-6 202931-10-0 202931-11-1 202931-12-2
202931-13-3 202931-14-4 202931-15-5 202931-16-6 202931-17-7
202931-18-8 202931-19-9 202931-21-3 202931-22-4 202931-23-5
202931-24-6 202931-25-7 202931-26-8 202931-27-9 202931-28-0
202931-29-1 202931-30-4 202931-31-5 202931-34-8 202931-36-0
202931-37-1 202931-38-2 202931-39-3 202931-40-6 202931-42-8
202931-43-9 202931-44-0 202931-45-1 202931-46-2 202931-47-3
202931-48-4 202931-49-5 202931-50-8 202931-51-9 202931-52-0
202931-53-1 202931-54-2 202931-55-3 202932-02-3 225642-02-4
225642-03-5 225642-04-6 225642-05-7 225642-06-8 225642-07-9
225642-08-0 225642-09-1 225642-10-4 225642-11-5 225642-16-0
225642-18-2 225642-21-7 225642-28-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triazolo-pyridazine deriv. GABAA ligands, and therapeutic use)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; S-TRIAZOLO(3,4-a) (5, 6, 7, 8)TETRAHYDROPHTHA LAZINES 1978, 5, HCAPLUS
(2) Delini-Stula, A; JOURNAL OF PSYCHIATRIC RESEARCH 1996, V30(4), P239 MEDLINE
(3) Dunn, E; SOCIETY FOR NEUROSCIENCE ABSTRACTS 1995, V21(1-3), P2046
(4) Hadingham, K; MOLECULAR PHARMACOLOGY 1993, V43, P970 HCAPLUS
(5) Hall, E; JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 1997, V17(8), P875 HCAPLUS
(6) Knoll Ag; WO 9632393 A 1996 HCAPLUS
(7) Lepetit Spa; EP 0085840 A 1983 HCAPLUS
(8) Merck Sharp & Dohme; WO 9834923 A 1998 HCAPLUS
(9) Mitsubishi Chemical Ind; JP 53021197 A 1978 HCAPLUS
(10) Richard, G; WO 9804559 A 1998 HCAPLUS
(11) Sanofi Sa; EP 0156734 A 1985 HCAPLUS
(12) Schering Ag; DE 19617862 A 1997 HCAPLUS
(13) Tarzia, G; FARMACO EDIZIONE SCIENTIFICA 1988, V43(2), P189 HCAPLUS

IT **15676-16-1**, Sulpiride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)

RN 15676-16-1 HCAPLUS
CN Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



L127 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:64683 HCAPLUS
DN 130:125258

TI Highly selective **butyrylcholinesterase** inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**

IN Greig, Nigel H.; Yu, Qian-sheng; Brossi, Arnold; Soncrant, Timothy T.; Hausman, Marvin

PA Axonyx, USA; National Institute of Health

SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DT **Patent**

LA English

IC ICM A61K031-40
ICS C07D209-58; C07D491-04; C07D491-048

CC 31-5 (Alkaloids)
Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9902154	A1	19990121	WO 1998-US14063	19980709	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	AU 9882931	A1	19990208	AU 1998-82931	19980709	<--
	AU 749088	B2	20020620			
	EP 949920	A1	19991020	EP 1998-933230	19980709	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	JP 2001500165	T2	20010109	JP 1999-508849	19980709	<--
	MX 9902293	A	20000731	MX 1999-2293	19990309	<--
	US 6410747	B1	20020625	US 1999-254494	19990617	<--
	US 2002094999	A1	20020718	US 2002-71488	20020207	<--
PRAI	US 1997-52087P	P	19970709	<--		
	WO 1998-US14063	W	19980709	<--		
	US 1999-254494	A3	19990617	<--		

GI



I II

AB The present disclosure relates to the discovery that highly selective butyrylcholinesterase inhibitors I [R = Me, Ph, C6H4Me-2, C6H4(CHMe2)-4, C6H4OMe-4, C6H4Me-4, C6H4(CNMe2)-2; R1 = H,Me, CH2Ph; X = NH, NMe, NCH2Ph, O, S] can prevent or treat **cognitive** impairments assocd. with aging or **Alzheimer**'s disease wherein said butyrylcholinesterase inhibitor has a selectivity ratio of butyrylcholinesterase inhibition to acetylcholinesterase inhibition of greater than about 15 to 1. A preferred butyrylcholinesterase inhibitor is N8-benzylnorcymserine [I; R = C6H4(CHMe2)-4, R1 = CH2Ph, X = NMe] and is prepd. via reaction of hexahydropyrrolo[2,3-b]indol-5-ol II with 4-(Me2CH)C6H4NCO in Et2O.

Cymserine showed protection against a cholinergic forebrain lesion-induced increase in .beta.-**amyloid** precursor protein and improves **cognitive** performance in rats at 05.mg/kg.

ST **Alzheimer** disease treatment cymserine deriv analog; **dementia** treatment cymserine deriv analog; butyrylcholinesterase inhibitor diagnosis **Alzheimer** disease; benzylnorcymserine prepn treatment **Alzheimer** disease; **amyloid** precursor protein secretion inhibitor cymserine

IT **Mental disorder**
(**dementia**; selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT Aging, animal
(disorder, **senility**; selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT **Alzheimer's disease**
(selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT Aging, animal
(**senility**; selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT **Amyloid precursor proteins**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-, secretion inhibitors; selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT 219920-75-9P, N8-Benzylnorcymserine 219920-88-4P, N1,N8-Bisbenzynorcymserine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT 219920-78-2P, N8-Norcymserine 219920-81-7P, N1,N8-Bisnorcymserine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT **57-47-6**, Physostigmine 6091-05-0, Physovenine 6091-57-2, Eseramine 19573-10-5, N8-Norphysostigmine 101246-66-6, Phenserine 114546-08-6, N1-Phenethylnorphysostigmine 116103-17-4, N1-Benzylnorphysostigmine 116103-18-5, N1-Norphysostigmine 116103-19-6, N1-Allylnorphysostigmone 116979-38-5, 4'-Methoxyphenserine 136092-41-6, Phensvenine 136092-42-7, Cymsvenine 145209-30-9, Tolserine 145209-31-0, N1-Benzylnortolserine 145209-32-1, N1-Nortolserine 145209-33-2, Tolsvenine 145209-34-3, 4'-Methylphenserine 145209-38-7, 2'-Isopropylphenserine 145209-39-8, Cymserine 145209-39-8D, carbon-11-labeled 145209-43-4, N1-Benzylnorphenserine 145209-44-5, N1-Norphenserine 145209-45-6, N1-Benzylnorcymserine 145209-46-7, N1-Norcymserine 145209-49-0, Thiaphenserine 145209-50-3, Thiatolserine 145209-51-4, Thiacymserine 145237-06-5, Thiaphysovenine 171075-53-9, N1-Phenethylnorphenserine 171075-56-2, N1-Phenethylnortolserine 193604-43-2, N8-Benzylnorphysostigmine 193604-44-3, N8-Benzylnorphenserine 193604-45-4, N8-Norphenserine 207729-61-1, N1,N8-Bisnorphenserine 207729-62-2, N1,N8-Bisnorphysostigmine 207729-68-8, N1,N8-Bisbenzylnorphenserine 207729-69-9, N1,N8-Bisbenzylnorphysostigmine 219920-69-1, N1-Phenethylnorcymserine 219921-12-7, N8-Benzylnortolserine

219921-17-2, N8-Nortolserine 219921-23-0, N1,N8-Bisbenzylnortolserine
219922-89-1, N1,N8-Bisnortolserine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT 9000-81-1, Acetylcholinesterase 9001-08-5, Butyrylcholinesterase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

IT 31027-31-3, 4-Isopropylphenyl isocyanate 193604-42-1, (-)-(3aS)-8-Benzyl-1,3a-dimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-ol 207729-66-6, (-)-(3aS)-1,8-Dibenzyl-3a-methyl-1,2,3,3a,8,8a-hexahydro-5-methoxypyrrolo[2,3-b]indole 207729-67-7, (-)-(3aS)-1,8-Dibenzyl-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-ol
RL: RCT (Reactant); RACT (Reactant or reagent)
(selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Brossi; US 5171750 A 1992 HCAPLUS
(2) Brossi; US 5378723 A 1995 HCAPLUS
(3) Greig; US 5409948 A 1995 HCAPLUS
(4) Hamer; US 5541216 A 1996 HCAPLUS
(5) Touvinen; Toxicol Appl Pharmacol 1996, V140(2), P364

IT **57-47-6**, Physostigmine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(selective butyrylcholinesterase inhibitors for the treatment and diagnosis of **Alzheimer**'s disease and **dementias**)

RN 57-47-6 HCAPLUS
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L127 ANSWER 21 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:239104 HCAPLUS
DN 128:279000
TI Method for the treatment of **neurological** or **neuropsychiatric** disorders using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.

IN Willis, Gregory Lynn
PA Willis, Gregory Lynn, Australia
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-135
ICS A61K031-165; A61N005-06; A61B017-00
CC 1-11 (Pharmacology)
Section cross-reference(s): 2
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9815267	A1	19980416	WO 1997-AU661	19971003 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9743725	A1	19980505	AU 1997-43725	19971003 <--
	AU 736005	B2	20010726		
	EP 964679	A1	19991222	EP 1997-941747	19971003 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001503394	T2	20010313	JP 1998-517016	19971003 <--
	US 6310085	B1	20011030	US 1999-285859	19990402 <--
	US 2002068692	A1	20020606	US 2001-971783	20011009 <--
PRAI	AU 1996-2745	A	19961004 <--		
	WO 1997-AU661	W	19971003 <--		
	US 1999-285859	A2	19990402 <--		

AB A method for the treatment and/or prophylaxis of a **neurol**. or **neuropsychiatric** disorder assocd. with altered dopamine function comprises subjecting a patient in need thereof to therapy which blocks and/or inhibits melatonin, precursors thereof and/or metabolic products thereof.

ST melatonin inhibition **neurol neuropsychiatric** disorder

IT **Brain, disease**
(**Gilles de la Tourette** syndrome; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Nervous system**
(**Huntington's chorea**; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Mental disorder**
(Pick's disease; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Stress, animal
(acute stress disorder; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Mental disorder**
(agoraphobia; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Nervous system**
(akathisia; **neurol**. or **neuropsychiatric** disorder

treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Appetite
(anorexia **nervosa**; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Melatonin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Anorexia
(cachexia; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Ion channel blockers
(calcium; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Mental disorder**
(**dementia**; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Mental disorder**
(depression, anxiety disorders due to; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Nervous system**
(dystonia, acute; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Antiparkinsonian agents**
(including for **neuroleptic**-induced **Parkinsonism**; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Behavior
(locomotor; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Disease, animal
(malignant syndrome; **neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Diagnosis
(melatonin in **neurol**. or **neuropsychiatric** disorder diagnosis)

IT **Anti-Alzheimer's agents**
Anxiolytics
Body weight
Drug delivery systems
Multiple sclerosis
Nervous system agents
Phototherapy
Psychotropics
Schizophrenia
Wernicke-Korsakoff syndrome
(**neurol**. or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Mental disorder**

(obsession-compulsion; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Anxiety
(panic disorder; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Movement disorders
(periodic limb movement syndrome and others; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Mental disorder**
(post-traumatic stress disorder; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Brain, disease**
(**stroke**; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Paralysis
(subnuclear, progressive; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Pineal gland
(surgical ablation or destruction; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **Nervous system**
(tardive dyskinesia; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Anti-ischemic agents
(trans-ischemic attack; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Drugs
(veterinary; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT Adrenoceptor antagonists
(.beta.-; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT **51-61-6**, Dopamine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(altered dopamine function; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT 1199-18-4 28289-54-5, MPTP
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT 9002-79-3, Melanocyte-stimulating hormone **29122-68-7**, Atenolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological

study); USES (Uses)
(**neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

IT 73-31-4, Melatonin 73-31-4D, Melatonin, precursors and metabolic products
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Adler, L; Psychopharmacology Bulletin 1991, V27(2), P107 MEDLINE
(2) Anon; EP 146113 HCAPLUS
(3) Anon; The Merck Manual of Diagnosis and Therapy, 16th Edition 1992, P1499
(4) Artemenko, A; 1996
(5) Chuprikov; US 5137018 1992
(6) Dubocovich; US 5093352 1992 HCAPLUS
(7) Dubocovich; US 5283343 1994 HCAPLUS
(8) Garcia-Talavera, B; 1984
(9) Glaxo Group Limited; WO 9529173 1995 HCAPLUS
(10) Koller, W; Arch Neurol 1987, V44, P921 MEDLINE
(11) Martindale; The Extra Pharmacopoeia 28th Edition 1982, P1337
(12) Miles, A; Biol Psychiatry 1988, V23, P405 HCAPLUS
(13) Searfoss; US 5046494 1991
(14) Sherer, M; Neurosci Lett 1985, V58(3), P277 MEDLINE
(15) Wilbur, R; Prog Neuro-Psychopharmacol and Biol Psychiat 1988, V12, P848

IT **51-61-6**, Dopamine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(altered dopamine function; **neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

RN 51-61-6 HCAPLUS
CN 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) (CA INDEX NAME)



IT **29122-68-7**, Atenolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**neurol.** or **neuropsychiatric** disorder treatment using therapy which blocks and/or inhibits melatonin, precursors thereof, and/or metabolic products thereof.)

RN 29122-68-7 HCAPLUS
CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



L127 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:161121 HCAPLUS
DN 128:213404
TI Sulfonyl fluorides for the treatment of **Alzheimer**'s disease
IN Moss, Donald Eugene
PA Board of Regents of the University of Texas System, USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-135
ICS A61K031-10
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9808497	A1	19980305	WO 1997-US15024	19970826 <--
	W: AU, CA, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5798392	A	19980825	US 1996-705858	19960828 <--
	US 5798392	C1	20020604		
	AU 9740915	A1	19980319	AU 1997-40915	19970826 <--
	AU 731755	B2	20010405		
	EP 921790	A1	19990616	EP 1997-938628	19970826 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000517317	T2	20001226	JP 1998-511856	19970826 <--
PRAI	US 1996-705858	A	19960828 <--		
	WO 1997-US15024	W	19970826 <--		

AB A pharmaceutical compn. is provided which comprises a sulfonyl fluoride and a pharmaceutically acceptable carrier. Also provided is a method of treating **Alzheimer**'s disease in an individual in need of such treatment, comprising administering to the individual a therapeutically ED of methanesulfonyl fluoride. Further provided is a method of enhancing **cognitive** performance in an individual in need of such treatment, comprising administering to the individual a therapeutically ED of methanesulfonyl fluoride.
ST sulfonyl fluoride **Alzheimer** disease; methanesulfonyl fluoride **Alzheimer** disease; **cognition** enhancer methanesulfonyl fluoride
IT **Parkinson's disease**
Parkinson's disease
(Guamanian **parkinsonism-dementia**; sulfonyl fluorides for **Alzheimer**'s disease treatment)
IT Erythrocyte
(acetylcholinesterase; sulfonyl fluorides for **Alzheimer**'s disease treatment)
IT **Nervous system**
(central, disease, acetylcholine insufficiency-related; sulfonyl fluorides for **Alzheimer**'s disease treatment)
IT **Mental disorder**

(**dementia**, Boxer's; sulfonyl fluorides for **Alzheimer**'s disease treatment)

IT **Anti-Alzheimer's agents**
Antiparkinsonian agents
Cognition enhancers
Drug delivery systems
Enzyme kinetics
Michaelis constant
(sulfonyl fluorides for **Alzheimer**'s disease treatment)

IT Lecithins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfonyl fluorides with other agents for **Alzheimer**'s disease treatment)

IT Sulfonyl halides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfonyl fluorides; sulfonyl fluorides for **Alzheimer**'s disease treatment)

IT 328-86-9 329-98-6, Phenylmethanesulfonyl fluoride 368-43-4, Benzenesulfonyl fluoride 368-72-9, 3-Amino-4-chlorobenzenesulfonyl fluoride 455-16-3, p-Toluenesulfonyl fluoride 498-74-8 558-25-8, Methanesulfonyl fluoride 754-03-0, Ethanesulfonyl fluoride 63805-73-2, 2-Propanesulfonyl fluoride 204260-09-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfonyl fluorides for **Alzheimer**'s disease treatment)

IT 51-84-3, Acetylcholine, biological studies 9000-81-1, Acetylcholinesterase 9001-08-5, Butyrylcholinesterase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sulfonyl fluorides for **Alzheimer**'s disease treatment)

IT **504-24-5**, 4-Aminopyridine 3576-73-6, RS86
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(sulfonyl fluorides with other agents for **Alzheimer**'s disease treatment)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Moss, D; Adv Behav Biol 1986, V29, P551 HCAPLUS
(2) Moss, D; Curr Res Alzheimer Ther:Cholinesterase Inhib 1988, P305 HCAPLUS
(3) Palacios-Esquivel, R; Neurobiol Aging 1993, V14(1), P93 HCAPLUS

IT **504-24-5**, 4-Aminopyridine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(sulfonyl fluorides with other agents for **Alzheimer**'s disease treatment)

RN 504-24-5 HCAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)

L127 ANSWER 23 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:147210 HCAPLUS
DN 128:201063
TI Cholinesterase inhibitors for treatment of **Parkinson**'s disease
IN Hutchinson, Michael
PA New York University, USA
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-55
ICS A61K031-40; A61K031-44; A61K031-505; A61K031-66; A61K031-195
CC 1-11 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9807431	A1	19980226	WO 1997-US14684	19970821 <--
	W: AU, CA, IL, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9740789	A1	19980306	AU 1997-40789	19970821 <--
	US 5965571	A	19991012	US 1997-915736	19970821 <--
PRAI	US 1996-22746P	P	19960822 <--		
	WO 1997-US14684	W	19970821 <--		

AB **Parkinson**'s disease can be treated with at least one cholinesterase inhibitor. The cholinesterase inhibitor has been found to alleviate both any symptoms of **dementia** as well as to reduce rigidity and improve motor function. E.g., on administration of 40 mg tacrine, building up to 60 mg/day after seven weeks, a patient exhibited remarkable improvements in **dementia** and rigidity.
ST cholinesterase inhibitor **Parkinsons** disease
IT **Parkinson's disease**
(cholinesterase inhibitors for treatment of **Parkinson**'s disease)
IT **Mental disorder**
(**dementia**; cholinesterase inhibitors for treatment of **Parkinson**'s disease)
IT 321-64-2, Tacrine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cholinesterase inhibitors for treatment of **Parkinson**'s disease)
IT 59-92-7, Levodopa, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cholinesterase inhibitors for treatment of **Parkinson**'s disease)
IT 52-68-6, Metrifonate **57-47-6**, Physostigmine 357-70-0, Galanthamine 987-78-0, Citicoline 101246-68-8, Heptastigmine 118909-22-1, Velnacrine maleate
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cholinesterase inhibitors for treatment of **Parkinson**'s disease)
IT 9000-81-1, Acetylcholinesterase 9001-08-5, Cholinesterase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; cholinesterase inhibitors for treatment of **Parkinson**'s disease)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Boar; US 5585378 A 1996 HCAPLUS
(2) Rosin; US 4948807 A 1990 HCAPLUS

IT **57-47-6**, Physostigmine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cholinesterase inhibitors for treatment of **Parkinson**'s disease)
RN 57-47-6 HCAPLUS
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L127 ANSWER 24 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:617007 HCAPLUS
DN 127:288186
TI Methods of treating **neurological** diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
IN Shapiro, Howard K.
PA USA
SO U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 26,617, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A01N043-04
ICS A01N061-00; C07H001-00; C08B037-08
NCL 514055000
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 5668117	A	19970916		US 1993-62201	19930629	<--
	CA 2166383	AA	19950112		CA 1994-2166383	19940628	<--
	WO 9501096	A1	19950112		WO 1994-US7277	19940628	<--
	W: AU, CA, JP						
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
	AU 9472144	A1	19950124		AU 1994-72144	19940628	<--
	AU 692454	B2	19980611				
	EP 707446	A1	19960424		EP 1994-921405	19940628	<--
	R: DE, FR, GB, IT						
	JP 08512055	T2	19961217		JP 1994-503597	19940628	<--
PRAI	US 1991-660561	B1	19910222	<--			
	US 1993-26617	B2	19930223	<--			
	US 1993-62201	A	19930629	<--			
	WO 1994-US7277	W	19940628	<--			

OS MARPAT 127:288186
AB Therapeutic compns. comprising an effective amt. of at least one carbonyl

trapping agent alone or in combination with a therapeutically effective of a co-agent or medicament are disclosed. The compns. are used to treat a mammal suffering from a **neurol**. disease characterized by covalent bond crosslinking between the **nerve** cells, other cellular structures and their intracellular and extracellular components, with disease-induced carbonyl-contg. aliph. or arom. hydrocarbons present in mammals.

ST carbonyl trap drug combination **neurol** disease

IT **Nervous system**
(**Huntington's chorea**; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Glutamate antagonists
(NMDA antagonists; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Sulfhydryl group
(agents contg.; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Nervous system**
(amyotrophic lateral sclerosis; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Antiarteriosclerotics
(antiatherosclerotics; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Sequestering agents
(bile acid; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Amines, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biogenic; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Ion channel blockers
(calcium; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 5-HT antagonists
Aging, animal
Alzheimer's disease
Analgesics
Anti-ischemic agents
Antiarrhythmics
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihistamines
Antihypertensives
Antioxidants
Anxiolytics
Carbonyl group
Cholinergic agonists
Cholinergic antagonists
Cognition enhancers
Dopamine agonists
Drug delivery systems
Drug interactions
Hypolipemic agents
Immunosuppressants
Multiple sclerosis
Nervous system agents

Parkinson's disease
Platelet **aggregation** inhibitors
Psychotropics
Radical scavengers
Tranquilizers
Vasodilators
(carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Carbonyl compounds (organic), biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Corticosteroids, biological studies
Hormones, animal, biological studies
Interferons
Lecithins
Phosphatidylcholines, biological studies
Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Nerve**
(conduction; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Drugs
Kidney
(conjugating agents facilitating kidney drug elimination; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Animal cell
(crosslinking; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Gastric emptying
(delayed; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Nerve, disease**
(**demyelination**, urinary incontinence in; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Ear
(disease, tinnitus; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Nervous system**
(disease; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Neurotransmission**
(enhancers; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Proteins, general, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(fibroblast; **neurofilament** crosslinking in chromosome 17 hereditary sensory and motor **neuropathy**)

IT Digestive tract
(gastroesophageal reflux; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Chromosome
(human 17, hereditary sensory and motor **neuropathy**; **neurofilament** crosslinking in chromosome 17 hereditary sensory

and motor **neuropathy**)

IT Bladder
(incontinence, from **Alzheimer's senile dementia** or other disease; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Heart, disease
(ischemia, agents for treatment of; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Brain**
(metab., enhancers; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Metabolism
(metabolites at risk of depletion; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Gangliosides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mixed cow brain; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Kidney, disease
(nephrotic syndrome, diabetes-related, agents for treatment of; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Crosslinking
(**nerve** cell; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Fibroblast
(**neurofilament** crosslinking in chromosome 17 hereditary sensory and motor **neuropathy**)

IT Cytoskeleton
(**neurofilament**; **neurofilament** crosslinking in chromosome 17 hereditary sensory and motor **neuropathy**)

IT **Nerve**
(**neuron**, crosslinking; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Nerve, disease**
(**neuropathy**, hereditary motor and sensory; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Anti-inflammatory agents
(nonsteroidal; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Nerve, disease**
(**peripheral neuropathy**, urinary incontinence in; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Carbohydrates, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plant, non-digestible, edible; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Polymers, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyamine-related; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Amines, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Nerve, disease**
(**polyneuropathy**, alc.; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(postsynaptic, agonists; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sequestrants; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Nervous system**
(spinocerebellar ataxia; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Reagents
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suspending; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Polycyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tricyclic; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **Diabetes mellitus**
(urinary incontinence in; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Blood
(viscosity, agents decreasing; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.-, .alpha.-adrenergic agents; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT Adrenoceptor antagonists
(.beta.-; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 9001-66-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A and B, inhibitors; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 51-84-3, Acetylcholine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agents enhancing synthesis, storage, or release of; carbonyl trapping agent combination with other drug for treatment of **neurol**.

diseases and etiol. related symptomol.)

IT 70-18-8, Glutathione, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agents facilitating activity of; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 50-18-0, Cyclophosphamide 54-96-6, 3,4-Diaminopyridine 56-40-6, Glycine, biological studies **57-47-6**, Physostigmine 58-56-0, Pyridoxine hydrochloride 58-85-5, Biotin 59-02-9 59-30-3, Folic acid, biological studies 59-43-8, Thiamine, biological studies 59-51-8, D,L-Methionine 59-67-6, Nicotinic acid, biological studies 59-92-7, Levodopa, biological studies 68-19-9, Vitamin B12 68-41-7, D-Cycloserine 72-19-5, L-Threonine, biological studies 79-83-4, Pantothenic acid 83-88-5, Vitamin B2, biological studies 98-92-0, Nicotinamide 137-08-6 137-58-6, Lidocaine 150-13-0, p-Aminobenzoic acid 302-79-4D, Retinoic acid, derivs. 302-84-1, Serine 321-64-2, Tacrine 357-70-0, Galanthamine 364-62-5, Metoclopramide 446-86-6, Azathioprine 456-59-7, Cyclandelate **504-24-5**, 4-Aminopyridine 645-88-5, Aminooxyacetic acid 657-24-9, Metformin 768-94-5, Amantadine 1134-47-0, Baclofen 1195-16-0 1406-18-4, Vitamin E 3200-06-4, Praxilene 3286-46-2, Sulbutiamine 4759-48-2, 13-cis-Retinoic acid 7235-40-7, .beta.-Carotene 7491-74-9, Piracetam 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9004-10-8D, Insulin, derivs., biological studies 11000-17-2D, Vasopressin, analogs 13345-51-2D, Prostaglandin B1, oligomers 14611-51-9, Selegiline 15301-69-6, Flavoxate 18601-90-6, Thiamine mononitrate 23210-56-2, Ifenprodil 24305-27-9, Thyrotropin releasing factor 28704-27-0 28860-95-9, Carbidopa 37758-47-7, Ganglioside GM1 41708-72-9, Tocainide 51012-32-9, Tiapride 51037-30-0, Acipimox **51481-61-9**, Cimetidine 54143-55-4, Flecainide 59865-13-3, Cyclosporine 66357-35-5, Ranitidine 72432-10-1, Aniracetam 73590-58-6, Omeprazole 76824-35-6, Famotidine 81098-60-4, Cisapride 103878-84-8, Lazabemide 105431-72-9, Linopirdine 196966-12-8, Anfacine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 63-74-1D, Sulfanilamide, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hypoglycemic; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 9000-81-1, Acetylcholinesterase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 9001-08-5, Cholinesterase 9015-82-1 9027-22-9, Decarboxylase 9028-31-3, Aldose reductase 9028-35-7, 3-Hydroxy-3-methylglutaryl CoA reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 50-67-9, Serotonin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reuptake inhibitors, antidepressants; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT 12794-10-4D, Benzodiazepine, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tranquilizers; carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

IT **57-47-6**, Physostigmine **504-24-5**, 4-Aminopyridine **51481-61-9**, Cimetidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(carbonyl trapping agent combination with other drug for treatment of **neurol**. diseases and etiol. related symptomol.)

RN 57-47-6 HCAPLUS
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 504-24-5 HCAPLUS
CN 4-Pyridinamine (9CI) (CA INDEX NAME)

RN 51481-61-9 HCAPLUS
CN Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L127 ANSWER 25 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:991057 HCAPLUS
DN 124:45735

TI Tacrine and cytochrome P450 oxidase inhibitors and methods of use for treatment of **Alzheimer**'s disease
IN Woolf, Thomas F.
PA Warner Lambert Co., USA
SO U.S., 15 pp. Cont.-in-part of U.S. 5,422,350.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K031-44
ICS A61K031-415; A61K031-505; A61K031-495
NCL 514297000
CC 1-11 (Pharmacology)
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 5466696	A	19951114		US 1993-100917	19930809	<--
	US 5422350	A	19950606		US 1992-943323	19920910	<--
	WO 9405296	A2	19940317		WO 1993-US8459	19930908	<--
	WO 9405296	A3	19940428				
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PT, RU, SK, UA						
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
	EP 659082	A1	19950628		EP 1993-923110	19930908	<--
	EP 659082	B1	20020206				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE						
	HU 70979	A2	19951128		HU 1995-704	19930908	<--
	HU 217845	B	20000428				
	JP 08501105	T2	19960206		JP 1994-507526	19930908	<--
	AU 669586	B2	19960613		AU 1993-52905	19930908	<--
	AU 9352905	A1	19940329				
	NZ 280680	A	20010831		NZ 1993-280680	19930908	<--
	AT 212845	E	20020215		AT 1993-923110	19930908	<--
	ES 2171419	T3	20020916		ES 1993-923110	19930908	<--
	FI 9501024	A	19950306		FI 1995-1024	19950306	<--
	NO 9500909	A	19950309		NO 1995-909	19950309	<--
PRAI	US 1992-943323	A2	19920910	<--			
	US 1993-100917	A	19930809	<--			
	NZ 1993-256940	A1	19930908	<--			
	WO 1993-US8459	W	19930908	<--			

OS MARPAT 124:45735
AB A method for treating **Alzheimer**'s disease in a patient comprises administering to the patient an effective amt. of tacrine in combination with a P 450 1A2 oxidase inhibitor. Preferably, the inhibitor is a heterocyclic guanidine. The in vivo and in vitro metab. of tacrine and a proposed pathway for irreversible binding of tacrine to human liver microsomal protein are also included. Enoxaxin, a specific P 450 1A2 inhibitor, not only decreased the rate of irreversible binding but also inhibited the overall rate of tacrine biotransformation.
ST cytochrome P450 oxidase inhibitor tacrine **Alzheimer**; P450 oxidase inhibitor tacrine **Alzheimer** disease
IT **Mental disorder**
(**Alzheimer**'s disease, tacrine and cytochrome P 450 oxidase inhibitors and methods of use for treatment of **Alzheimer**'s disease)
IT 9038-14-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cytochrome P 450 1A2-dependent, inhibitors; tacrine and cytochrome P 450 oxidase inhibitors and methods of use for treatment of **Alzheimer**'s disease)
IT 54-05-7, Chloroquine 64-99-3, Ethimizol 74011-58-8, Enoxacin 80288-49-9, Furafylline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(tacrine and cytochrome P 450 oxidase inhibitors and methods of use for

treatment of **Alzheimer**'s disease)

IT 124027-47-0, 1-Hydroxytacrine 130073-98-2, 2-Hydroxytacrine
130073-99-3, 4-Hydroxytacrine 136051-80-4
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence)
(tacrine and cytochrome P 450 oxidase inhibitors and methods of use for treatment of **Alzheimer**'s disease)

IT 321-64-2, Tacrine
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(tacrine and cytochrome P 450 oxidase inhibitors and methods of use for treatment of **Alzheimer**'s disease)

IT 56-49-5, 3-Methylcholanthrene 120-58-1, Isosafrole 1746-01-6, 2,3,7,8-Tetrachlorodibenzo-p-dioxin 6051-87-2, .beta.-Naphthoflavone 9035-51-2, Cytochrome P 450, biological studies 11097-69-1, Aroclor 1254
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tacrine and cytochrome P 450 oxidase inhibitors and methods of use for treatment of **Alzheimer**'s disease)

IT **51481-61-9** 52378-41-3 52378-49-1 52378-50-4 52378-59-3
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tacrine and cytochrome P 450 oxidase inhibitors and methods of use for treatment of **Alzheimer**'s disease)

IT **51481-61-9**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tacrine and cytochrome P 450 oxidase inhibitors and methods of use for treatment of **Alzheimer**'s disease)

RN 51481-61-9 HCAPLUS

CN Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L127 ANSWER 26 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN **1995:940662** HCAPLUS

DN **124:45496**

TI Clinical pharmacokinetics of physostigmine in patients with **Alzheimer**'s disease

AU Asthana, Sanjay; Greig, Nigel H.; Hegedus, Lajos; Holloway, Harold H.; Raffaele, Kathleen C.; Schapiro, Mark B.; Soncrant, Timothy T.

CS National Institute Aging, National Institutes Health, Bethesda, MD, USA

SO Clinical Pharmacology and Therapeutics (St. Louis) (**1995**), 58(3), 299-309
CODEN: CLPTAT; ISSN: 0009-9236

PB Mosby-Year Book

DT Journal

LA English

CC 1-11 (**Pharmacology**)

AB Our objective to study the pharmacokinetic and pharmacodynamic properties of physostigmine in subjects with **Alzheimer**'s disease. Plasma physostigmine concn. and butyrylcholinesterase inhibition were measured in blood samples collected during and after a single high-dose (1 to 1.5 mg for 45 to 60 min) and a sustained low-dose steady-state i.v. infusion in nine subjects with **Alzheimer**'s disease. Escalating doses (0.5

to 25 mg/day) were administered during a 2-wk period. A dose (2 to 12 mg/day) that optimized **cognition** in each subject was identified and then administered in a randomized, double-blind, placebo-controlled crossover design for 1 wk. The elimination half-life of physostigmine was 16.4 .+-. 3.2 (SE) minutes. Clearance and vol. of distribution were 7.7 .+-. 0.9 (SE) L/min and 2.4 .+-. 0.6 (SE) L/kg, resp. Butyrylcholinesterase inhibition half-life was 83.7 .+-. 5.2 (SE) minutes. During sustained steady-state infusion, plasma physostigmine concn. ($r = 0.95$) and butyrylcholinesterase inhibition ($r = 0.99$) were linearly correlated with the dose. In five **cognitive** responders, the memory enhancement was significantly correlated ($r = 0.86$; $p < 0.05$) with butyrylcholinesterase inhibition. These results showed that, in **cognitive** responders, memory enhancement by physostigmine in **Alzheimer**'s disease is correlated directly to the magnitude of plasma cholinesterase inhibition. Furthermore, during single-dose conditions, the dynamic half-life is five-fold longer than the kinetic half-life.

ST physostigmine **Alzheimer** disease

IT **Mental disorder**
(**Alzheimer**'s disease, clin. pharmacokinetics of physostigmine in humans with **Alzheimer**'s disease)

IT **57-47-6**, Physostigmine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(clin. pharmacokinetics of physostigmine in humans with **Alzheimer**'s disease)

IT **57-47-6**, Physostigmine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(clin. pharmacokinetics of physostigmine in humans with **Alzheimer**'s disease)

RN 57-47-6 HCAPLUS

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L127 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1995:723143 HCAPLUS

DN 123:102794

TI Pharmaceutical compositions and use thereof for treatment of **neurological** diseases and etiologically related symptomatology.

IN Shapiro, Howard K.

PA USA

SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A01N043-04
ICS A01N061-00; A61K031-73; C12Q001-68; G01N033-00; G01N033-539
CC 1-11 (Pharmacology)
FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	WO 9501096	A1	19950112		WO 1994-US7277	19940628	<--
	W: AU, CA, JP						
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
	US 5668117	A	19970916		US 1993-62201	19930629	<--
	AU 9472144	A1	19950124		AU 1994-72144	19940628	<--
	AU 692454	B2	19980611				
	EP 707446	A1	19960424		EP 1994-921405	19940628	<--
	R: DE, FR, GB, IT						
	JP 08512055	T2	19961217		JP 1994-503597	19940628	<--
PRAI	US 1993-62201	A	19930629	<--			
	US 1991-660561	B1	19910222	<--			
	US 1993-26617	B2	19930223	<--			
	WO 1994-US7277	W	19940628	<--			

AB Pharmaceutical compns. for treatment of several **neurol**. diseases and pathophysiol.-related symptomol. in other body tissues, including peripheral **neuropathies**, secondary symptomol. of diabetes, **Alzheimer**'s disease, **Parkinson**'s disease, alc. **polyneuropathy** and age-onset symptomol., as well as analogous veterinary diseases, are disclosed. Spurious pathol. chem. crosslinking of normal intracellular structures is a fundamental aspect of these **neurol**. diseases. Covalent bond crosslinking of protein and lipid subcellular elements appear to underlie the formation of polymd. **aggregates** of **neurofilaments** and other structural proteins, and lipofuscin. Pharmacol. intervention in some **neurol**. diseases using water-sol., small mol. wt. primary amines or their derivs. as oral therapeutic agents, may compete with cellular protein and lipid amine groups for reaction with disease-induced carbonyl-contg. aliph. and arom. hydrocarbons. Primary pharmacol. agents include 4-aminobenzoic acid and derivs. thereof to facilitate kidney recognition and removal. This invention also includes oral use of nonabsorbable polyamine polymers and amine-related co-agents, such as chitosan, to covalently bind and sequester potentially toxic carbonyl compds. present in the diet, oral use of known antioxidant co-agents and related nutritional factors and use of the primary agent and co-agents in combination with known medicaments for treatment of these **neurol**. diseases.

ST **neurol** disease drug
IT Gangliosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GM1; pharmaceutical compns. for treatment of **neurol**. diseases contg.)
IT Nitrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drugs; pharmaceutical compns. for treatment of **neurol**. diseases contg.)
IT Gene, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for chromosome 17 Charcot-Marie-Tooth disease; identification of)
IT Hernia
(hiatalp; pharmaceutical compns. for treatment of)
IT **Parkinsonism**
(pharmaceutical compns. for treatment of)
IT Antihistaminics

Antioxidants
Immunomodulators
Vasoconstrictors
Vasodilators
(pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT Alfalfa
Antiarrhythmics
Anticonvulsants and Antiepileptics
Antidepressants
Anxiolytics
Cholinergic antagonists
Lecithins
Mastic (resin)
Muscle relaxants
Parsley
Soybean meal
Watercress
Yeast
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT Amino acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selenium-contg.; pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT **Mental disorder**
(**Alzheimer**'s disease, pharmaceutical compns. for treatment of)

IT Tranquilizers and **Neuroleptics**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antipsychotics, pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT Rice
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bran, pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT **Nerve, disease**
(**diabetic neuropathy**, pharmaceutical compns. for treatment of)

IT **Nervous system**
(disease, pharmaceutical compns. for treatment of)

IT **Nervous system**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(disease, amyotrophic lateral sclerosis, pharmaceutical compns. for treatment of)

IT Bladder
(disease, incontinence, pharmaceutical compns. for treatment of)

IT Hearing
(disorder, tinnitus, pharmaceutical compns. for treatment of)

IT **Neurotransmitter** agonists
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dopaminergic, pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mercapto-contg., pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT Ubiquinones
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reduced, pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT Bran

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rice, pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT 9027-22-9, Decarboxylase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, peripheral; pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT 9001-08-5, Cholinesterase 9001-66-5, Monoamine oxidase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT 50-81-7, L-Ascorbic acid, biological studies 52-67-5, Penicillamine 52-90-4, Cysteine, biological studies 55-63-0, Trinitroglycerin 56-40-6, Glycine, biological studies 56-45-1, Serine, biological studies 57-11-4, Octadecanoic acid, biological studies 59-02-9, .alpha.-Tocopherol 59-43-8, Vitamin B1, biological studies 59-92-7, Levodopa, biological studies 60-23-1, Cysteamine 62-46-4, Thioctic acid 63-68-3, Methionine, biological studies 63-75-2, Arecoline 68-41-7, D-Cycloserine 70-18-8, Glutathione, biological studies 70-51-9, Deferoxamine 72-19-5, L-Threonine, biological studies 77-92-9, biological studies 87-33-2, Isosorbide dinitrate 150-13-0, 4-Aminobenzoic acid 302-79-4, Retinoic acid 357-70-0, Galanthamine 364-62-5, Metoclopramide 456-59-7, Cyclandelate 532-11-6, Sulfarlem 557-04-0, Magnesium stearate 616-91-1, N-Acetylcysteine 645-88-5, Aminooxyacetic acid 1406-16-2, Vitamin D 4759-48-2, 13-cis-Retinoic acid 6027-13-0, Homocysteine 7235-40-7, .beta.-Carotene 7631-86-9, Silica, biological studies 7757-93-9, Dicalcium phosphate 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9000-01-5, Gum arabic 9000-07-1, Carrageenan 9000-28-6, Gum ghatti 9000-30-0, Gum guar 9000-36-6, Gum karaya 9000-40-2, Locust bean gum 9000-47-9, Gum mesquite 9000-65-1, Gum tragacanth 9004-32-4 9004-34-6, Cellulose, biological studies 9004-61-9, Hyaluronic acid **9005-25-8**, Starch, biological studies 9007-28-7, Chondroitin sulfate 9012-76-4, Chitosan 9056-36-4, Keratan sulfate 11000-17-2D, Vasopressin, analogs 11103-57-4, Vitamin A 11138-66-2, Xanthan gum 12001-79-5, Vitamin K 12629-01-5, Human growth hormone 13345-51-2D, Prostaglandin B1, oligomers 15301-69-6, Flavoxate 16679-58-6, Desmopressin 18481-23-7 19750-45-9 23210-56-2, Ifenprodil 23288-49-5, Probucol 24305-27-9, Thyrotropin-releasing factor 31329-57-4, Nafronyl 51012-32-9, Tiapride **51481-61-9**, Cimetidine 59937-28-9, Malotilate 60719-82-6, Alaproclate 64224-21-1, Oltipraz 66357-35-5, Ranitidine 73590-58-6, Omeprazole 75060-92-3 75364-47-5 76824-35-6, Famotidine 81098-60-4, Cisapride 103878-84-8, Lazabemide 105431-72-9, Linopirdine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT 27555-50-6, Poly-N-acetyl-D-glucosamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.-(1.fwdarw.4), pharmaceutical compns. for treatment of **neurol**. diseases contg.)

IT **9005-25-8**, Starch, biological studies **51481-61-9**, Cimetidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treatment of **neurol**. diseases contg.)

RN 9005-25-8 HCAPLUS
CN Starch (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 51481-61-9 HCAPLUS
CN Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L127 ANSWER 28 OF 28 HCAPLUS COPYRIGHT 2003 ACS
AN 1994:672190 HCAPLUS
DN 121:272190
TI Methods for the treatment of bradyphrenia in **Parkinson**'s disease using **histamine** antagonists
IN Kaminski, Ram
PA Mount Sinai School of Medicine of the City University of New York, USA
SO U.S., 4 pp. Cont.-in-part of U.S. 5,177,081.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K031-44
ICS A61K031-425; A61K031-415; A61K031-34
NCL 514357000
CC 1-11 (Pharmacology)
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5352688	A	19941004	US 1992-954258	19920930	<--
	US 5070101	A	19911203	US 1991-655759	19910214	<--
	US 5177081	A	19930105	US 1991-743254	19910809	<--
	US 5453428	A	19950926	US 1993-117503	19930907	<--
	WO 9407490	A1	19940414	WO 1993-US9191	19930927	<--
	W: AU, CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	EP 665749	A1	19950809	EP 1993-923142	19930927	<--
	EP 665749	B1	20000322			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	AU 688739	B2	19980319	AU 1993-52929	19930927	<--
	AU 9352929	A1	19940426			
	AT 190840	E	20000415	AT 1993-923142	19930927	<--
	IL 107134	A1	19980222	IL 1993-107134	19930928	<--
	US 5547969	A	19960820	US 1994-314414	19940928	<--
	US 5889033	A	19990330	US 1995-496608	19950629	<--
PRAI	US 1991-655759	A3	19910214	<--		
	US 1991-743254	A2	19910809	<--		
	US 1992-954258	A2	19920930	<--		
	US 1993-117503	A3	19930907	<--		
	WO 1993-US9191	W	19930927	<--		

AB **Neuropsychiatric** symptoms of **Parkinson**'s Disease, particularly the symptoms of apathy-amotivation and mental slowing, can be ameliorated by treating a patient suffering from **Parkinson**'s Disease with a **histamine** H2 -antagonist (e.g. famotidine, ranitidine) that passes the blood-brain barrier. The H2 -antagonists may be co-administered with other compds., e.g. **histamine** H1-antagonists or dopamine receptor agonists, which are known to be useful in the treatment of **Parkinson**'s Disease, and can be formulated with such other compds. into a therapeutic compn.
ST bradyphrenia **Parkinson** disease **histamine** antagonist; famotidine ranitidine bradyphrenia **Parkinson** disease
IT **Parkinsonism**
(treatment of bradyphrenia in **Parkinson**'s disease using

histamine antagonists)
IT **Blood-brain barrier**
(treatment of bradyphrenia in **Parkinson**'s disease using **histamine** antagonists crossing the blood-brain barrier)
IT Antihistaminics
(H1, treatment of bradyphrenia in **Parkinson**'s disease using **histamine** H2 antagonists and other therapeutic agents)
IT Antihistaminics
(H2, treatment of bradyphrenia in **Parkinson**'s disease using **histamine** antagonists)
IT **Mental disorder**
(bradyphrenia, treatment of bradyphrenia in **Parkinson**'s disease using **histamine** antagonists)
IT **Neurotransmitter** agonists
(dopaminergic, treatment of bradyphrenia in **Parkinson**'s disease using **histamine** antagonists and other therapeutic agents)
IT **51481-61-9**, Cimetidine 66357-35-5, Ranitidine 69014-14-8, Tiotidine 73147-56-5D, 1,2,5-Oxadiazol-3-amine, derivs. 73590-58-6, Omeprazole 76824-35-6, Famotidine 76824-35-6D, Famotidine, homologs and isomers 76963-41-2, Nizatidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of bradyphrenia in **Parkinson**'s disease using **histamine** antagonists)
IT **51481-61-9**, Cimetidine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of bradyphrenia in **Parkinson**'s disease using **histamine** antagonists)
RN 51481-61-9 HCAPLUS
CN Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 12:22:18 ON 09 APR 2003)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 12:22:34 ON 09 APR 2003
E BAMDAD R/AU
L1 9 S E4,E5
E BAMDAD C/AU
L2 31 S E3-E7
E BAMBAD R/AU
L3 2 S E4
L4 1 S E2
L5 32 S L1-L4
SEL DN AN 15
L6 1 S L5 AND E1-E3
SEL DN AN L5 11
L7 1 S E4-E6 AND L5
L8 42 S R (1W) ATENOLOL

```
L9          192 S ALPHA () (METHYLNOREPINEPHRINE OR METHYL NOREPINEPHRINE)
L10         243 S ERBSTATIN
L11           0 S ICI 11551 HYDROCHLORIDE
L12           0 S ICI 11 551 HYDROCHLORIDE
L13           0 S ICI 11 551
L14           0 S ICI 11551
L15           0 S ICI11551
L16           0 S INDATRALINE HYDROCHLORIDE
L17          32 S INDATRALINE
L18          28 S CGS 12066A
L19           0 S CGS 12066A DIMALEATE
L20           0 S CGS 12066# DIMALEATE
L21       22447 S URACIL
L22           0 S L21 (L) 5 TRIFLUOROMETHYL 5 6 DIHYDRO
L23           0 S 1 ALLYL 3 7 DIMETHYL 8 (1W) SULPHOPHENYL XANTHINE
L24           1 S 1 ALLYL 3 7 DIMETHYL 8 (1W) SULFOPHENYL XANTHINE
L25           1 S ADSPX
L26           1 S 1 ALLYL 3 7 DIMETHYL 8 (1W) SULFOPHENYLXANTHINE
L27           0 S ALPHA BETA METHYLENE ADENOSINE 5 TRIPHOSPHATE DILITHIUM
L28          28 S ALPHA BETA METHYLENE ADENOSINE 5 TRIPHOSPHATE
L29           4 S HISTAMINE (S) ALPHA METHYL (S) DIHYDROCHLORIDE
L30           0 S HISTAMINE 1 METHYL HYDROCHLORIDE
L31           3 S 1 3 DIHYDRO 1 2 HYDROXY 5 TRIFLUOROMETHYL PHENYL 5 TRIFLUOROM
L32           5 S N6 CYCLOPENTYL 9 METHYLADENINE
L33         252 S N6 METHYLADENOSINE
L34          34 S S 4 NITROBENZYL 6 THIOINOSINE
L35           0 S P P DI ADENOSINE 5 TETRAPHOSPHATE TRIAMMONIUM
L36           0 S P P DIADENOSINE 5 TETRAPHOSPHATE TRIAMMONIUM
L37         399 S DIADENOSINE(1W)TETRAPHOSPHATE
L38           0 S L37 AND TRIAMMONIUM
L39         233 S BRL 37344
L40           9 S THIOPERAMIDE MALEATE
L41           0 S 3 3 4 4 TETRAMETHOXY N METHYL DIPHENETHYLAMINE
L42           3 S 3 3 4 4 TETRAMETHOXY(L)DIPHENETHYLAMINE
L43           0 S FORMYL(S)HYDROXY(S)PHOSPHONOXY(S)PYRIDIN?(S)BENZENEDISULFONIC
L44           0 S FORMYL(S)HYDROXY(S)PHOSPHONOXY(S)PYRIDIN?(S)BENZENE DISULFONI
L45           9 S 4 DAMP METHIODIDE
L46          14 S FLUOROHEXAHYDRO(S)?DIFENIDOL?
L47          77 S P F HHSID
L48       53551 S HISTAMINE
L49          16 S HISTAMINE (S) METHYL (S) DIHYDROCHLORIDE
                SEL RN L6

     FILE 'REGISTRY' ENTERED AT 13:39:27 ON 09 APR 2003
L50          60 S E7-E66
L51          23 S 50-33-9 OR 52-01-7 OR 55-10-7 OR 57-47-6 OR 61-76-7 OR 65-28-
L52          18 S 4789-68-8 OR 13153-27-0 OR 13523-86-9 OR 15307-79-6 OR 15676-
L53           3 S 147416-96-4 OR 148440-81-7 OR 153587-01-0
L54           8 S 147416-96-4 OR 148440-81-7 OR 153587-01-0 OR 109292-91-3 OR 1
L55          49 S L51-L54
L56          16 S L50 NOT L55
L57           3 S 501-75-7/CRN AND CLH
L58           1 S 121741-03-5
                E CGS 12066/CN
L59           1 S E4
L60           1 S E5
L61          14 S L56 NOT L57-L60
L62          49 S C6H11N3/MF AND NCNC2/ES
L63           7 S L62 AND ALPHA
                SEL RN 2 4 5 6
L64           4 S E1-E4/CRN AND CLH
L65          58 S L55,L57-L60,L64
L66          13 S L50 NOT L65
```

```
L67          71 S L65,L66

     FILE 'HCAPLUS' ENTERED AT 14:48:46 ON 09 APR 2003
L68       34870 S L67
L69           2 S L5 AND L68
L70           1 S L69 NOT TUMOR MARKER
L71           2 S L6,L7,L70
                E MINERVA/PA,CS
L72         725 S MINERVA?/PA,CS
L73           3 S L72 AND L68
L74           1 S L71 AND L73
L75           2 S L71,L74
L76          24 S L68 AND NEURODEGEN?
                E BRAIN, DISEASE/CT
L77      105952 S E3+NT
                E E3+ALL
                E E169+ALL
L78      333107 S E4+NT
                E E52+ALL
L79        7577 S E4,E3+NT
                E PRION DISEASE/CT
                E E4+ALL
L80        2209 S E7,E8,E6+NT
                E E16+ALL
L81        3022 S E7,E6+NT
                E PRION DISEASE/CT
L82           4 S E11
                E NERVOUS SYSTEM/CT
L83      275499 S E3+NT
                E E3+ALL
L84           2 S E4
                E NERVE, DISEASE/CT
L85        2111 S E49-E53
                E E3+ALL
L86       27704 S E3+NT
                E E53+ALL
L87      141419 S E5,E4+NT
L88       25802 S E25+NT OR E26+NT OR E34+NT
L89      237038 S E29+NT OR E30+NT OR E31+NT OR E32+NT OR E28+NT
                E ALZHEIMER/CT
                E E9+ALL
L90       17662 S E6,E5+NT OR E23+NT OR E24+NT OR E25+NT OR E26+NT OR E27+NT OR
                E PARKINSON/CT
                E E6+ALL
L91        9632 S E4,E3+NT
L92        3267 S E9+NT OR E10+NT
                E SICKLE CELL/CT
                E E4+ALL
L93        1818 S E4+NT
                E DIABETES/CT
                E E10+ALL
L94       52706 S E5,E4+NT
L95       13963 S E8+NT OR E10+NT
                E AMYLO/CT
                E E41+ALL
L96        2430 S E2+NT
L97       67813 S E6+NT
                E DEMENTIA/CT
                E E4+ALL
L98        3709 S E2
L99        8544 S L68 AND L77-L98
                E AGGREGAT/CT
                E E6+ALL
```

```
L100        7784 S E1
                 E AGGREGAT/CT
                 E E18+ALL
L101        4246 S E1
L102       87941 S E1+NT
L103          16 S L99 AND L100-L102
L104          10 S L67 (L) THU/RL AND L76
L105          64 S L67 (L) THU/RL AND 99
L106          60 S L103-L105 AND (PY<=2000 OR PRY<=2000 OR AY<=2000)
L107          53 S L106 AND (PHARMACOL? OR PHARMACEUT?)/SC
L108          15 S L106 AND (PHARMACOL? OR PHARMACEUT?)/SX
L109           5 S L106 NOT L107,L108
L110          55 S L106-L108 NOT L109
L111           3 S L110 AND 9/SC,SX
L112          52 S L110 NOT L111
                 SEL DN AN 8 27 49
L113           3 S E1-E9 AND L112
L114           4 S L75,L113
L115           5 S L68 AND L100,L101
L116        8137 S L99 AND (PY<=2000 OR PRY<=2000 OR AY<=2000)
L117         818 S L116 AND L67 (L) THU/RL
L118         378 S L117 AND P/DT
L119         230 S L118 AND US/PC
L120         129 S L117 AND (DEMENT? OR ?PARKINSON? OR ?ALZHEIMER? OR ?AMYLOID?
L121          16 S L117 AND (SENILE OR SENILITY OR SENESCEN? OR GELSOIN OR POLYN
L122         132 S L120,L121
L123          53 S L122 AND L119
L124          24 S L123 AND (NEUROLOG? OR NEUROPSYCH? OR ALZHEIMER? OR PARKINSON
L125          28 S L114,L124
L126          28 S L125 AND L1-L49,L68-L125
L127          28 S L126 AND (NEUR? OR NERV? OR ?ALZHEIMER? OR ?PARKINSON? OR COG
```

2 ANSWER 54 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 57-47-6 REGISTRY
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Physostigmine (8CI)**
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-
OTHER NAMES:
CN (-)-Eserine
CN **(-)-Physostigmine**
CN Cogmine
CN Eserine
CN Esromiotin
CN MCV 4484
CN NIH 10421
CN Physostol
FS STEREOSEARCH
DR 511-49-9, 50975-37-6
MF C15 H21 N3 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3055 REFERENCES IN FILE CA (1962 TO DATE)
33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3057 REFERENCES IN FILE CAPLUS (1962 TO DATE)
23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>

6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:400745 CAPLUS
DOCUMENT NUMBER: 119:745
TITLE: Cholingeric sensitivity of irides from donors with various pathological conditions and lens implants
AUTHOR(S): Patil, Popat N.; Mauger, Thomas F.
CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1992), 346(6), 620-8
CODEN: NSAPCC; ISSN: 0028-1298
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In vitro, iris contractions after muscarinic agonists were measured in mg of tension change and the concn. producing 50% of the response was expressed as EC50 .mu.mol/L. Although the av. EC50 value of carbachol in the iris sphincter of the donors with **diabetes** or Parkinson's disease did not change significantly when compared with the control, the max. contraction of the tissue from the diseased state was increased significantly. Thus, in addn. to the well known denervation supersensitivity of the iris-dilator, the iris-sphincter also develops adaptive sensitivity changes. Antimuscarinic drug treatment in some Parkinson's patients interfered with the estn. of supersensitivity in vitro studies. The enhanced response of carbachol at the low temps. or the relative potency of carbachol and pilocarpine in the tissue obtained from the diseased donors was not significantly different from that of controls. Based on EC50 values, the potency of arecoline on the iris was 1/3 that of carbachol. Significantly lower EC50 values of carbachol were found in irides which were in contact with open loop type anterior chamber lens implants compared with those in contact with the closed loop anterior chamber lens implants. Max. responses of irides to carbachol were less when the tissue was in contact with open loop lens compared with those in contact with closed loop anterior chamber implants. Irides from many donors having unilateral or bilateral replacement of the artificial lenses responded with EC50 of carbachol which was approx. equal to that of the contralateral eye. The max. difference between EC50 values of the left and right iris was less than 5 fold. Paired irides with asym. surgical procedures responded unequally to carbachol. The dissocn. const. KB of atropine (1 nmol/L) at 17.degree. was equal to that obsd. at 37.5.degree.. The KB values of himbacine, methoctramine and pirenzepine were 120, 1500, 120 nmol/L, resp. From one tissue to another, there was a spread in the dissocn. const. value of pirenzepine indicating that human iris sphincter may contain a heterogenous population of muscarinic receptors.

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN **30200-05-6** REGISTRY
CN Benzenebutanoic acid, .beta.-(aminomethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butyric acid, 4-amino-3-benzyl- (8CI)
FS 3D CONCORD
MF C11 H15 N O2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMCATS
      (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 148553-50-8
L10 1 148553-50-8
(148553-50-8/RN)

=> d

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN **148553-50-8** REGISTRY
CN Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)-
OTHER NAMES:
CN CI 1008
CN PD 144723
CN Pregabalin
FS STEREOSEARCH
MF C8 H17 N O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
      (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

100 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
103 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 206749-40-8/rn or 256418-06-1/rn or 256418-07-2/rn
1 206749-40-8/RN
1 256418-06-1/RN
1 256418-07-2/RN
L11 3 206749-40-8/RN OR 256418-06-1/RN OR 256418-07-2/RN

=> d 1-3

L11 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS
RN **256418-07-2** REGISTRY
CN Benzenepentanoic acid, .beta.-(aminomethyl)-.delta.-ethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H21 N O2
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L11 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS
RN **256418-06-1** REGISTRY
CN Cyclohexanepentanoic acid, .beta.-(aminomethyl)-.delta.-ethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H27 N O2
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L11 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2003 ACS
RN **206749-40-8** REGISTRY
CN Cyclohexanebutanoic acid, .beta.-(aminomethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C11 H21 N O2

CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1962 TO DATE)
6 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=>

RN 57-47-6 REGISTRY
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Physostigmine (8CI)**
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-
OTHER NAMES:
CN (-)-Eserine
CN **(-)-Physostigmine**
CN Cogmine
CN Eserine
CN Esromiotin
CN MCV 4484
CN NIH 10421
CN Physostol
FS STEREOSEARCH
DR 511-49-9, 50975-37-6
MF C15 H21 N3 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3055 REFERENCES IN FILE CA (1962 TO DATE)
33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3056 REFERENCES IN FILE CAPLUS (1962 TO DATE)
23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)